against cancer

Fox Chase Cancer Center Annual Report 2009

TEAMING UP AGAINST CANCER

333 Cottman AvenuePhiladelphia, PA 19111-24971-888-369-2427www.FoxChase.org

Presorted StandardU.S. PostagePAIDPhiladelphia, PAPermit #3187

Fox Chase Cancer CenterA

nnual Report 20

09

TEAM

ING

UP A

GA

INST C

AN

CER

2807W1:2807W1 3/10/10 3:38 PM

2 Message from the President3 Faculty & Patients29 The Year in Review38 Message from the Chairman39 Friends & Supporters49 Faculty & Leadership

“What I find exciting about my job is the pace of development of new treatment options, and that I can assure my patients thatwe can look forward to many new and effective therapies in our lifetime.”

Mitchell R. Smith, Medical Oncologist

2807W1:2807W1 3/11/10 2:47 PM

WHAT ISFOX CHASE? There are many ways to measure Fox Chase Cancer Center: by the number of

patients it serves, the discoveries made by its researchers, the square feet occupied

by its buildings. But Fox Chase is, more than anything, defined by the people it

touches and is touched by: The doctors and scientists who come to work motivated

by the possibility of saving lives. The patients themselves, many of whom face the

challenge of a lifetime. And the friends and supporters whose generosity and caring

create new hope for the future. Together, these individuals make up the team that

is Fox Chase.

THESE ARE THEIR STORIES.

Fox Chase Cancer Center 1

2807W2:2807W2 3/10/10 3:40 PM Page 1

Cancer is a complex problem.

It will take a diverse community of individuals with a formidable array of talents, from doctors and laboratory scientists to behavioral

researchers and philanthropists, to solve that problem. That’s why Fox Chase takes the team approach, bringing top experts in

various fields together to share knowledge and generate ideas. By collaborating across disciplines, they can more quickly bring us closer

to the answers, closer to the cures. ■ Anyone who has experienced cancer, on whatever level, can tell you it isn’t something you deal

with alone. Just ask the Fox Chase nurses who spend their days caring for patients—not just administering medications, but also

keeping spirits up, for both the patients and each other. Ask the dedicated scientists who rely on collaboration and cooperation to

carry out the exacting research studies that promise to reveal new understanding. Most of all, ask the patients—or perhaps you don’t need

to. If you have had cancer, you know: It is when you’re facing severe adversity—like cancer—that you realize just how much you need other

people. ■ Like a painting composed of a thousand individual dots of color, Fox Chase is made up of a rich mosaic of individual people

and their stories. These pages introduce just a few: The gifted surgeon for whom patients are like family; the marathon runner who is

back on the track after a diagnosis of stage IV breast cancer; the donor and former patient who honors her parents’ memory by

giving back, year after year, to the place where they were cared for. ■ The courage, compassion, and perseverance embedded in these

stories solidify my hope and conviction that we will, indeed, solve the cancer problem—together. If you are not already part of the Fox

Chase team, I invite you to join us.

Sincerely,

MICHAEL V. SEIDEN, M.D., Ph.D.

President and Chief Executive Officer

2 Fox Chase Cancer Center

2807W2:2807W2 3/10/10 3:40 PM Page 2

FACULTY& PATIENTS

“At no other cancer center will you find such a unique and intense set of collaborations—cross-disciplinary efforts in which ideas, inspiration, and insightflow from lab bench to bedside and back again.”

Michael V. Seiden, President and Chief Executive Officer

2807W2:2807W2 3/10/10 3:40 PM Page 3

HANDSAND HEART

2807W2:2807W2 3/11/10 5:40 PM Page 4

One afternoon in October, a group ofsurgeons, anesthesiologists, and

nurses, still clad in operating-room scrubs,gathered around a cake decorated with arobot to celebrate a milestone: the comple-tion of Fox Chase’s 1,000th robotic surgery.Among them, wearing a colorful bouffantsurgical cap, was urologic surgeon RosaliaViterbo, whose recent operation on a kidney had brought the Center to the landmark tally.

Since her arrival in 2007, Viterbo hashelped make Fox Chase one of the leadinghospitals in the country in the use of robotic surgery, as well as other minimally invasive techniques, to treat cancer. At 35, she has performed hundreds of the operations, including innovative, organ-sparing kidney and bladder procedures.

“Patients experience a lot of benefit withthe robot-assisted approach,” Viterbo says, “including shorter hospital stays and lessscarring.” For some, she adds, the technol-ogy can mean the difference between afunctioning kidney and a lifetime of dialysis.

“The robot”—officially, the da Vinci® SurgicalSystem—allows the surgeon to view the surgical field on a monitor while sitting at a console and using controls to manipulate instruments that are inserted into the patient’s body through small incisions. Thesystem enhances precision by magnifyingthe surgical site and presenting it in three dimensions, as well as filtering outhand tremors.

Useful as it is, the robot is just one ofViterbo’s many tools. She also performshands-on laparoscopic techniques (shownat left) and is equally comfortable under-taking conventional surgery when needed.“I use my entire armory,” she says. “Thebottom-line goal is getting rid of the patient’s cancer.”

Viterbo glimpsed early on the powerful potential of medicine. After arriving in theUnited States from Italy at 10, she was thefirst in her family to master English, and thelogical choice to accompany family memberson doctor visits—especially her grandmother,who suffered with respiratory disease.“Whenever my grandmother came homewith a good response to treatment,” she recalls, “everyone—nine children and 20 grandchildren—would be relieved andjoyful. I thought to myself, it would beamazing to be able to make that happen.”

She credits some of her physician’s aptitudesto her parents: “I come from passionatepeople with good hand skills,” she says,noting that her mother was a seamstress,her father a carpenter.

Viterbo takes an empathetic approach toher patients that she believes is particularlyimportant in her specialty, which covers theurinary system and male reproductive organs.As she puts it, “You’re taking care of personal things in private areas. I tell all my patients: ‘Once I take care of you, you’refamily.’ I think they do better knowingsomeone is treating their situation in a personal way.”

THE TEAM: The Department of SurgeryRosalia Viterbo and her colleagues inthe department of surgery representsome of the top cancer surgeons in thecountry. All Fox Chase surgeons arefellowship-trained, meaning they haveup to four years of additional trainingafter their residency that focuses onthe complex techniques involved incancer surgery, including minimally invasive procedures.

“Fox Chase is among only a handful ofinstitutions worldwide using minimallyinvasive surgery to treat patients withnearly all types of cancer,” notesRobert G. Uzzo, department chairman.“Our surgeons not only know how to use the technology, but they havemore experience using it for cancersurgery than most surgeons in thecountry.”

Minimally invasive surgery, which involves operating with special instruments and very small incisions, typically results in less bleeding, fewercomplications, and faster recovery forpatients. If surgery is the first step of amulti-stage treatment plan, the patientcan move forward more quickly to the next step.

Minimally invasive techniques have not completely replaced open, or conventional, surgery, which remainsthe best solution for many complexcases. Working with the other membersof the patient’s treatment team, FoxChase surgeons determine the bestapproach for each individual case.

Surgeon Rosalia Viterbo brings finely honed technical skills—and a lot of caring—to the patients she calls “family.”


FACULTY

2807W2:2807W2 3/10/10 3:40 PM Page 5

FULLTHROTTLE

PATIENT

2807W2:2807W2 3/10/10 3:41 PM Page 6

PART OF A POSITIVE OUTCOME

Specialists in the plastic andreconstructive surgery program at Fox Chase tailor reconstruction procedures tothe needs and desires of eachpatient. “The restoration ofthe breast is an integral partof treating women for breastcancer,” notes program chiefNeal S. Topham. Fox Chasesurgeons have expertise inleading-edge reconstructionoptions, including advancedtechniques like the “freeTRAM flap” procedure, whichuses a patient’s own abdomi-nal tissue. Says Topham:“Each woman’s circumstanceswill be different, and choosingthe procedure that is right for the individual is critical toa positive outcome.”

“I used to say, ‘One of these days...’ Well,‘one of these days’ is today.”

That’s the credo of Tijuana Smith, a 37-year-old wife, mother, and breast cancersurvivor. As soon as she finished hermonths-long course of treatment at FoxChase, the fit and energetic Smith fulfilledher lifelong dream of earning her motorcycle license and buying a bike—a Suzuki GS500, to be exact.

Her “live-for-today” attitude is a changefrom the heaviness she felt when she wasdiagnosed in 2007. That weight began tolift with her first appointment at Fox Chase,a meeting that included medical oncologistRamona F. Swaby, surgeon Richard J. Bleicher, and plastic and reconstructive surgeon Sameer A. Patel, all members ofthe breast cancer treatment team.

“Everybody was right there,” Smith recalls.“They all knew my case. The doctors explained things to me in a way I could understand; they broke everything downand made it easier for me to focus on myhealth.”

The Center’s coordinated approach reas-sured her. “When I first got my diagnosis, I was at a different hospital,” she explains.“When I was told what I would need to doto beat this cancer, they left me to find myown resources.” That included undertakingthe time- and energy-consuming tasks offinding her own specialists and coordinatingwith her insurance company.

At Fox Chase, she says, everyone is cluedin: “I go to one appointment, and they already know what time my next appoint-ment is. When I get there, my information is already there.”

As part of her treatment, Smith opted for amastectomy with reconstruction. Bleicherand Patel worked together to accomplishboth procedures in a single operation. For the reconstruction, Patel used the state-of-the art “free TRAM flap” procedure.TRAM—transverse rectus abdominus myocutaneous—refers to using tissue andfat from a woman’s stomach (a “tummytuck”) to build a natural-looking and natural-feeling breast.

“Dr. Patel’s reconstructive surgery made melook even better than before,” says Smith,who has since logged beach time in a two-piece bathing suit. “That’s how good he is.”

During her chemotherapy, Smith notes, sheappreciated the “total care” she receivedfrom both clinicians and administrators,from attending to the side effects of chemo to helping coordinate her insurance benefits. She calls those extra-mile efforts “golden.”

Since finishing treatment, Smith has resumed working—and working out, liftingweights to rebuild the upper-arm strengthshe lost during treatment. And when theweather is nice, it’s a good bet you’ll findher heading for the garage, helmet in hand,not wanting to waste a minute.

Her experience with breast cancer gave Tijuana Smith a new outlook on life.


2807W2:2807W2 3/10/10 3:41 PM Page 7

AT THE FOREFRONT

2807W2:2807W2 3/10/10 3:41 PM Page 8

I f it weren’t for her being such a “peopleperson,” Shelly B. Hayes might have gone

into bioengineering. As it was, she choseradiation oncology as her career—and Fox Chase, a recognized leader in the field,for her residency training.

Last year, Hayes returned to the Centerfrom private practice in Virginia to take on anew role as director of Fox Chase’s recentlyopened satellite radiation treatment facility.Located in Buckingham, Pennsylvania,some 20 miles north of the main Fox Chasecampus in Philadelphia, the facility offersthe latest in radiation therapy technology—with a personal touch.

“I’m very patient-focused,” Hayes notes. “Ibelieve each patient comes in with a uniqueset of concerns and needs; my goal is tomeet those needs.” She works with a teamof expert radiation physicists and dosagespecialists to develop an individualizedtreatment plan for each patient.

Hayes discovered her aptitude for workingwith people when she was an undergradu-ate majoring in bioengineering. While sheliked the intellectual rigor of physics andmath, she realized she didn’t want to spendthe rest of her life “behind a computer.” So she decided to become a doctor.

In medical school, she had anotherepiphany. When students were offered the

opportunity to do rotations in various clinical settings, she chose radiation oncology, thinking she would get a glimpseof a field she wasn’t likely to specialize in.To her surprise, she found it fascinating.“It’s very diverse,” she says. “We treat bothmen and women of all ages and do lots ofdifferent procedures.” She also discoveredthat treatment planning involved the samekind of problem-solving skills as physicsand math.

At Fox Chase Cancer Center Buckingham,Hayes works with such leading-edge technology as the CyberKnife®, a roboticsystem that can be used to treat canceranywhere in the body. An imaging systemtracks the tumor to correct for movement,such as occurs with the patient’s breathing. Because it is so precise, the CyberKnife candeliver a high dose of radiation in fewertreatments.

“The CyberKnife is one of the tools at theforefront of radiation technology,” Hayessays. “It allows us to treat patients more effectively, with fewer side effects and in ashorter period of time, and it has openedup new possibilities for patients who previously had few options.”

Hayes is excited by the prospect of makingworld-class radiation treatment available to more patients. And she has found a new use for her “people skills”: serving asher facility’s ambassador as she spreads theword to area physicians and patients.

THE TEAM: The Department of Radiation Oncology

Radiation therapy is a critical compo-nent of treatment for many cancer patients, and Fox Chase’s radiation oncology program—which includes radiation oncologists specializing inspecific cancers, as well as radiationtherapists, dosage specialists, and physicists—is one of the largest andmost advanced in the country.

“Radiation oncology is a technology-based specialty,” notes departmentchairman Eric M. Horwitz, “and FoxChase is expert at integrating state-of-the-art technology into treatment.”

The Center has pioneered some ofmedicine’s most effective radiationtherapy technologies, from intensity-modulated radiation therapy, or IMRT,to ultrasound- and radiofrequency-guided targeting. These tools can precisely target even a moving tumorand deliver radiation tailored to its unique contours and density with minimal effect on surroundinghealthy tissue.

Because its radiation oncologists workwith the foremost medical physicistsand makers of medical equipment todevelop new or improved applicationsof their technology, Fox Chase oftencan provide new treatments to patients before they’re available atother facilities.

Shelly B. Hayes brings the latest technology together with personalized care as director of Fox Chase’s new satellite radiation treatment center.


FACULTY

2807W2:2807W2 3/10/10 3:41 PM Page 9


LOOKINGAHEAD

2807W2:2807W2 3/10/10 3:41 PM Page 10


Medical oncologist Roger B. Cohen tooka nontraditional path to his position as

director of Fox Chase’s Phase I clinical trialsprogram. Having trained as a physician, he spent nearly a decade doing laboratoryresearch, then joined the Food and DrugAdministration’s Center for Biologics Evaluation and Research as a medical officer in 1989. It was at the FDA, while reviewing the results of clinical trials in patients with advanced cancer, that he wasstruck by the potential of biologics, a newtype of drug made from living organisms.

“I thought they offered real hope for the future,” Cohen recalls. “I said to myself, ‘Iwould much rather be participating in theprocess than watching it.’ So after complet-ing a fellowship in medical oncology at theNational Cancer Institute, he embarked on anew career path that landed him at FoxChase in 2001. Today, Cohen treats patientswith a variety of cancers, including lung,breast, thyroid, and head and neck, in addition to researching the development ofnew therapies.

In Phase I trials, experimental drugs aretested for the first time in people, often patients with advanced cancer who lackstandard treatment options. While the primary goal of the trials is to assess thedrugs’ safety, researchers also look for effectiveness against the cancer.

“Phase I trials are really quite complex froman emotional and ethical standpoint,”Cohen says. “Our primary responsibility asdoctors is to treat people and try to makethem better, but in Phase I we are also conducting an experiment.” The reality ofthe situation can weigh on a physician who cares about each of his patients, asCohen does.

Progress is slow when it comes to develop-ing new therapies. More than 85 percentare eliminated after Phase I, and Cohen advises “realistic expectations.” Still, he hasseen significant improvements in patientoutcomes and quality of life over the pasttwo decades and believes there eventuallywill be cures, or long-lasting remissions, for many cancers that currently are difficultto treat.

In the meantime, he continues to find hopeand inspiration in his work. “Oncologists areoptimists,” he says. “When I offer a clinicaltrial to a patient, I am hopeful that the drugis going to prove beneficial.”

He is hopeful, too, that his difficult work willpay off for future patients. “There are fewthings more gratifying than to watch a drugyou gave in a Phase I study ‘grow up’ andhelp large numbers of people live betterand longer,” he says. “That’s why I do this.”

THE TEAM: The Clinical Trials Program

Staying at the forefront of cancer caremeans continually seeking new andbetter treatments. That’s why FoxChase is a leader in clinical trials—studies that evaluate experimentaltherapies, as well as new diagnostictests and other technologies. The Center has approximately 225 trialsunder way at any given time, giving itspatients access to the latest promisingdrugs.

Because there are few effective treatments available for sarcoma, acancer that affects bone and otherconnective tissues, medical oncologistMargaret von Mehren regularly turns to the Center’s clinical trials for novel therapies. “For patients diagnosedwith these cancers, clinical trials are a vital source of hope,” says vonMehren, director of the sarcoma program.

Clinical trials involve four phases:Phase I evaluates safety; Phase IImeasures effectiveness; Phase III compares the new therapy to a currentone; and Phase IV, conducted after the drug is approved for sale, includeslong-term safety studies. Though itsPhase I program is its most active, Fox Chase participates in all phases.

The Center strives to ensure that patients can maintain their relationshipswith their own physicians while partici-pating in clinical trials, von Mehrennotes. As a result, she says, “they don’tfeel abandoned…and as providers, we can continue to follow our patientsand get a sense of what a new drug isabout, so we feel more invested in the trials.”

As director of Phase I clinical trials, Roger Cohencares for the cancer patients of today whilecreating new hope for those of tomorrow.


FACULTY

2807W2:2807W2 3/10/10 3:42 PM Page 11

LEADING MAN

2807W2:2807W2 3/10/10 3:42 PM Page 12


THINK TWICE

Questioning a doctor’s initialrecommendation can be agood idea, especially when itcomes to a step like major sur-gery. “If a patient is advisedto have their entire kidney removed, their first questionto the doctor should be, ‘Whycan’t my kidney be saved?’says urologic surgeon RobertG. Uzzo. “In the vast majorityof localized kidney cancers,the tumor can be cured andthe kidney can be saved, usu-ally using a minimally invasivetechnique. Patients shouldchallenge their doctors toachieve these goals or referthem to someone experiencedin doing so.”

The jolts of pain in his stomach were excruciating. So much so that John Roley,

who rarely goes to the doctor, checkedhimself into the emergency room.

The pain turned out to be a blessing in dis-guise when tests revealed the unexpected:Roley had golf ball-sized, cancerous masseson each of his kidneys. “If the pain hadgone away, I would have never known,” the78-year-old says, adding that after gettingover the initial shock of hearing he had apotentially life-threatening disease, he wasdetermined to beat it.

A father, grandfather, and great-grandfather,Roley is a man of many talents and pursuits.He sings, dances, exercises, and co-owns a fiberglass manufacturing company—and he wasn’t ready to give any of it up. “I remember saying to the doctor, ‘OK, I havecancer. Now how do I get rid of it?’ ” he says.

Roley was ready to take that doctor’s advice and undergo a two-phase procedurethat would have required large incisions oneach side of his midsection, many weeks of recovery, and possibly even dialysis, untilhis fiancé Lucy Hooper encouraged him toconsider other options. The couple’s desirefor a second opinion led them to Fox Chaseand one of the top kidney surgeons in the country: Robert G. Uzzo, chairman of thedepartment of surgery, who specializes inrobot-assisted minimally invasive surgery.

Fox Chase is among just a handful of institutions worldwide using robotics totreat a wide array of cancers, and aftermeeting with Roley, Uzzo suggested usingthe state-of-the-art technology to removethe tumors on his kidneys.

The surgery would require two small incisions and leave very little scarring, and Roley’s recovery time would be lessthan half that required by open surgery. Convinced this was the way to go, Roley underwent surgery on his left kidney inMarch 2008 and returned three monthslater to have the procedure performed on his right kidney.

“Two days later, I was discharged from the hospital at 5 p.m. and by 9, I was at adance,” he says. “Sure, I was sitting on thesidelines, but I was there and I felt good.”

Today, cancer-free, Roley is busy runninghis business, escorting Lucy to weekendballroom dances, and planning a spring wedding. Positive thinking andprayers helped him move beyond cancer, he says, as did the caring staff at FoxChase.

“The people are so friendly,” Roley says.“They make you feel good about life and living.”

John Roley is an active guy, and he wasn’t about to let kidney cancer slow him down.


PATIENT

2807W2:2807W2 3/10/10 3:42 PM Page 13

PREVENTIONPIONEER

2807W2:2807W2 3/10/10 3:42 PM Page 14


The early detection and prevention ofdisease had interested Veda N. Giri

since she was a medical student, so whenher mentor encouraged her to do researchin prostate cancer genetics during her fellowship at the University of Michigan, sheleapt at the opportunity. The experienceproved life-changing.

Not only did Giri develop an interest inprostate cancer—a relatively unusual specialty for a woman—but her mentor became Giri’s role model for combining aclinical practice and research with a familylife. Today, Giri is director of prostate cancerrisk assessment at Fox Chase—and themother of two children, ages 6 and 9.

Giri isn’t sure whether she provides a modelof work-life balance but figures “just goingthrough the process—seeing patients,doing bench work, writing grants,publishing, and raising a family—might setan example.”

Her busy work life focuses on efforts tobetter understand—and prevent—prostatecancer. Established in 1996, the prostatecancer risk assessment program currentlyfollows nearly 800 men ages 35 to 69 whoare at heightened risk for prostate cancerbecause of family history or race; AfricanAmericans are particularly prone to the disease. The men receive screenings, accessto genetic counseling, and education aboutlowering their risk.

Because some families share a hereditaryrisk not only for prostate cancer but forother cancers as well, participants’ relativesmay also undergo risk assessment. For thatreason, Giri works hand-in-hand with physicians who specialize in evaluating riskfor breast, ovarian, and colorectal cancer.

When she’s not in the clinic, Giri is often inthe lab. Unlike with other cancers, there isno widely accepted genetic test forprostate cancer, so she researches geneticmarkers that indicate a heightened risk ofthe disease, using blood samples donatedby program participants. (See "GeneticMarker" article on page 35.) She also worksclosely with urologists, radiation oncologists,and medical oncologists to determine thebest approaches to early detection.

So far, about 10 percent of the men enrolledin the program have been diagnosed withprostate cancer—a higher incidence thanthose the same age in the general population. In about a quarter of the cases,the cancer was aggressive.

The patients’ cancers were caught at a curable point, Giri believes, thanks largelyto their being in the program and under thewatchful eyes of Fox Chase physicians.

“These were men who were only in theirlate 40s, early 50s,” she notes. “Forprostate cancer, that’s young. It’s very satisfying that we were able to make a difference.”

THE TEAM: The Risk Assessment Program

Fox Chase has long been a pioneer incancer prevention and risk assessment.In 1991, the Center established theMargaret Dyson Family Risk Assessment Program—one of the firstinitiatives of its kind in the country—to provide personalized preventionand detection services to women at heightened risk of breast or ovariancancer. Since then, the Center has expanded its efforts—now collectivelyknown as the Risk Assessment Program—to include prostate cancer,gastrointestinal cancers, melanoma,and lung cancer.

The program’s holistic approach includes family members. “Instead of a collection of blood samples, we have a collection of people with their histories and experiences," says founding director Mary B. Daly. “Wefollow them over the years and conductfollow-ups to see whether their healthhas changed.” Besides providingscreening, counseling, and education,the program has compiled a wealth ofinformation on more than 150,000 individuals. More than 6,000 families are enrolled.

The program includes research into the factors that influence cancer risk—efforts that draw on laboratory scientists, as well as clinicians, epidemiologists, and biostatisticiansacross the Center. In one lab, researchersmight work with a pulmonologist todevelop new imaging techniques todetect early-stage lung cancer, whilein another, they consult with a gastroenterologist about using abotanical product to treat ulcerativecolitis, a potential risk factor for colon cancer. “We’re very much ateam,” Daly says.

Medical oncologist Veda Giri leads a pioneering effort to get the jump on prostate cancer.


FACULTY

2807W2:2807W2 3/10/10 3:43 PM Page 15

In Fox Chase’s busy infusion room, awhite-coated figure stands out among

the rainbow of nurses’ scrubs: nurse practi-tioner Karon Martyn keeps a watchful eyeon patients receiving their chemotherapytreatments, ready to lend a hand if needed.

Infusion room nurses play a critical role: administering drugs, monitoring patients, andproviding comfort and support over monthsor even years of therapy. Martyn strives toensure both patient safety and efficiency.

“We’re always trying to streamline theprocess while also improving care,” shesays. “In addition to minimizing treatmentdelays, we’ve been able to increase the rateof some infusions and safely do in 30 minutes what used to take 90.”

Martyn was connected to Fox Chase—andthe infusion room—long before she becamean employee. Her aunt, Catherine Toomey,has been an infusion room nurse for thepast 40 years. The two are exceedinglyclose. “She raised me,” Martyn says. “She’slike my mom.”

Twelve years ago, as an undergraduateworking toward her bachelor’s degree innursing, Martyn obtained an externship caring for medical and surgical patients atFox Chase. After graduating, she was offered a full-time position on the staff andlater joined her aunt as part of the infusionroom nursing team.

Martyn subsequently returned to school toearn her master’s degree, which enabledher to become certified as a registered

nurse practitioner. She then took up anewly created position at Fox Chase: infusion room nurse practitioner. “They figured I would be a good fit,” says Martyn,who has held the position since November2008. “I know how this room works.”

As a nurse practitioner, Martyn specializesin managing the side effects that can occurwith cancer treatment. She collaborateswith the Center’s medical oncologists, whosometimes request pre-infusion exams forpatients or consult with her on the adminis-tration of particular drugs. If a patient runsinto complications during treatment, Martyn can provide immediate help, as shehas the authority to prescribe symptom-relieving drugs.

Patients receive other support as well. Martyn believes the infusion room has a“special vibe” because of the close-knitfriendships among its nurses. “We’re likefamily,” she says. And those relationshipsbolster efforts to make patients’ experienceas positive as possible. “We try to keepthings light,” Martyn says, noting the nursessometimes use humor to draw patients intotheir lively circle. “We know everyone ishere with a serious illness, and we want ourpatients’ treatment time to be as free ofstress as possible. It’s what we do to lessen their burden.”

THE TEAM:The Department of Nursing

Nurses are on the front lines when itcomes to caring for cancer patients,and Fox Chase’s nursing departmenthas earned a national reputation forthe quality of its care. The departmentrecently earned Magnet status—theAmerican Nurses Association’s highesthonor—for the third consecutive time.

“This award is especially significantbecause studies have shown a correla-tion between Magnet status and betterpatient outcomes,” notes Joanne Hambleton, vice president for nursingand patient services. “The fact thatonly 2 percent of the hospitals in thecountry have received Magnet re-designation speaks to the magnitudeof this accomplishment.” Fox Chasewas the first acute-care hospital inPennsylvania, and the first cancerhospital in the nation, to earnthe designation.

Despite the challenges inherent in oncology nursing, Hambleton says,nurses like working at Fox Chase—aphenomenon she attributes to theCenter’s supportive environment andthe fact that “they know they are part of a team dedicated to making a positive difference in patients’ lives.”

Nurse practitioner Karon Martyn helps keep the treatment process running smoothlyin the all-important infusion room.


FACULTY

2807W2:2807W2 3/10/10 3:43 PM Page 16

17

AT THE READY

2807W2:2807W2 3/11/10 5:06 PM Page 17

AGAINST THE ODDS

2807W2:2807W2 3/10/10 3:43 PM Page 18

19Fox Chase Cancer Center 19

Life has thrown Missy Dougherty manycurveballs—and possibly one miracle.

At 31, after spending a frustrating, funk-inducing summer slogging to the doctor’soffice looking for answers, Dougherty finally discovered what was causing her persistent fatigue and nausea: She had ovarian cancer.

“That summer was just awful,” recallsDougherty, a mother, graduate student,bartender, and high school basketballcoach. “I felt like I had been hit by a truck. I knew something was wrong, but I didn’tknow what.”

Still, the diagnosis, revealed after she insistedon surgery to remove a lemon-sized cystfrom her ovary, surprised both Doughertyand her gynecologist.

“Two days after my surgery, she called andsaid, ‘The pathology wasn’t what we thought.The cyst is malignant.’ At that point, I waslistening to her but not really listening toher,” Dougherty says. “I handed the phoneto my husband and whispered. ‘Somethingis really wrong.’ It was definitely a punch in the face.”

Soon after, a specialist was recommendinga radical hysterectomy. However, Doughertyand her husband, Brendan, were hesitant.Unconvinced that the cancer was in the latestages, the pair—whose only child, BrendanJunior, was 2—didn’t want to shut the dooron another pregnancy.

After a friend suggested Fox Chase, the couple found hope in Mark A. Morgan, chiefof gynecologic surgical oncology, who hadpreserved the fertility of other women withovarian cancer. Dougherty put her faith in him and went back into the operatingroom, where the surgeon removed oneovary and left the other intact. She wokefrom surgery to see her husband crying.“He told me my cancer was caught earlyand we might be able to conceive anotherchild,” she says.

Just months after completing chemotherapy,Dougherty learned she was pregnant. MollyElizabeth Dougherty, born in July 2009, has been called a miracle. To her mother,the baby is something else: Proof that lifecan continue after cancer. “Now I tell people, ‘You can have a positive outcome.You can move forward and make it to theother side,’ ” says Dougherty, who went onto appear on the “Dr. Oz” television show to raise awareness of ovarian cancer.

Her own persistence likely helped save herlife, but Dougherty credits Fox Chase andits staff for giving her hope. “It’s a placethat exudes positive energy,” she says.“They never let you think anything otherthan that you are going to beat the cancer,and that’s a good feeling.”

When ovarian cancer stacked the odds againsther having another child, Missy Doughertyplaced her bets with a Fox Chase surgeon.

LEADING EFFORTS

Ovarian cancer, which affectsmore than 20,000 women inthe United States each year,has been called a silent killerbecause its symptoms canmimic other conditions. Fox Chase is leading efforts to better understand and treat the disease; Center researchers developed thechemotherapy regimen that isthe current worldwide standardfor treating the disease andare taking part in a nationalclinical trial of a therapy withthe potential to further revolutionize treatment. Tolearn more about ovarian cancer research and treatmentat Fox Chase, visitwww.fccc.edu/cancer/types/gynecological/ovarian.

PATIENT

2807W2:2807W2 3/10/10 3:43 PM Page 19

“When I was 10, I didn’t know whatcancer was,” says social worker

Anjali Albanese, “and suddenly there wassomeone in my house going throughchemotherapy.” That someone was hergrandmother, who stayed with Albanese’sfamily while undergoing treatment.

The illness and her grandmother’s deathtwo years later challenged the entire family.“I remember wondering, who helps peoplewith this?” she says. “I vowed that if I could, one day I would make it a differentexperience for some other family.”

From then on, Albanese prepared to become a social worker. If she had to do aproject for school, she wrote about cancerand its impact on people’s lives. In college,she focused on psychology and publichealth. The final piece of the puzzle was amaster’s degree in social work, which shecompleted in 1999. “Professionally, I nevervacillated,” she says. “I always knew what Iwanted to do.”

Now a 10-year Fox Chase veteran, Albaneseworks with her colleagues in the depart-ment of social work services to providecounseling and other assistance to patientsand their families.

In counseling sessions, she searches outpeople’s strengths. “I ask about the kinds ofthings that got them through rough situations in the past,” she says. By drawingon those relationships, activities, and

beliefs, patients often realize they can facetheir current difficulties. Sometimes, allthey need is a sounding board. “When people get to talk about their situation,”she says, “they often realize, ‘It’s okay. I cando this; I can figure this out.’ ”

Besides counseling, Albanese has been active in patient education. Along withnurse Kathleen Smith, she developed andcontinues to teach a class designed to prepare patients for chemotherapy. “It tellspeople what to expect, both physically andemotionally, and patients generally find itreduces their anxiety,” she says. She alsohelped to create “Facing Forward,” a lungcancer awareness program for which, each November, she organizes panel discussionsincluding medical experts, social workers,and patients in honor of Lung CancerAwareness Month.

Albanese appreciates Fox Chase for confronting not only cancer itself, but alsothe emotional and psychosocial needs associated with the disease. “What would it mean to be a comprehensive cancer center,” she says, “if you treated less thanthe whole person?”

THE TEAM:The Department of Social Work Services

While Fox Chase’s expert clinicians concentrate on treating disease, itsdedicated social workers assist patients and their families with a widerange of needs, from emotional support to finding a place to stay.

Fox Chase made the commitmentdecades ago to address not just thedisease itself, but also its emotionaland social impact, says LuanneChynoweth, director of the departmentof social work services. “This holisticapproach is embedded in our philoso-phy of care,” she says.

The department’s nine specialists areall degree-holding social workers withyears of training. Individual counselingis a key component of the servicesthey provide. “Getting a cancer diagnosis can knock the wind out ofpeople,” says social worker Anjali Albanese. “We teach them how tobreathe again.” The department alsooffers a variety of support groups, including Kids’ Night Out for childrenof cancer patients.

In addition, the social workers conductclasses for patients, staff, and the community and help patients with logistical issues that can seem overwhelming during treatment, from transportation and lodging to insurance and financial matters. Theyhave little trouble keeping busy: About 500 people seek help from the department each month.

Social worker Anjali Albanese helps patientsand families navigate the many challengesthat can come with a cancer diagnosis.


FACULTY

2807W2:2807W2 3/10/10 3:43 PM Page 20

21

TREATING THE WHOLE

PERSON5

2807W2:2807W2 3/10/10 3:43 PM Page 21

MAKING ADIFFERENCE

2807W2:2807W2 3/10/10 3:44 PM Page 22


Growing up with a sister who hadchronic renal failure meant Andrea M.

Barsevick spent a lot of time in hospitals.She recalls the special assistance her familyreceived during those long, difficult days.

“We were almost always hooked up with asocial worker or nurse who was chargedwith working with people dealing withchronic disease,” she says. “My sister diedat 25, and when I look back at that experience, those people made a big difference. I decided that’s the kind of person I wanted to be.”

Barsevick became a registered nurse andworked at hospital bedsides for a dozenyears. During that time, she earned a master’s degree in psychiatric nursing andmoved to the general medical floor of auniversity hospital, where she supple-mented her clinical work by helping othernurses deal with the psychological andquality-of-life issues—such as pain, depression, and fatigue—that many patientsexperience during treatment. Seeing a needfor greater understanding of such issues,she obtained a doctorate in nursing research and shifted her focus to scienceand teaching.

Today, as Fox Chase’s director of nursingresearch, Barsevick studies quality of life incancer patients and survivors. Her research constitutes an important component of theCenter’s growing survivorship program, as it demonstrates the long-term impact of cancer and its treatment. For example,studies show that about a third of survivorsexperience increased fatigue that continuesat least a year after treatment ends.

“Quality of life is defined as people’s subjective ideas about what’s happening tothem,” Barsevick notes. “It’s not somethingyou can measure biologically or observe. It really is about an individual’s perceptionof what their life is like and how it’s beenaffected by their illness and treatment.”

Working with colleagues across the country, Barsevick studies the experiencesof patients and survivors and works to develop guidelines for alleviating their suffering through psychosocial measures.This work has led Fox Chase and other cancer hospitals to implement efforts suchas teaching survivors ways to conservetheir energy while managing tasks. Hercontribution, she believes, is a fitting tributeto her sister.

“I got into this work because of my sister,”she says, “but my determination is reinforced all the time by being around cancer patients and being able to say thatthe work I’m doing is making a difference.We really can help people.”

THE TEAM: The Survivorship Program

Because the effects of cancer and its treatment don’t always end when therapy ends, Fox Chase’s full spectrumof care includes a growing focus onsurvivorship. The estimated 11 million-plus cancer survivors living in theUnited States face many physical,emotional, and psychological challenges, from chronic pain to fatigue and depression.

“These issues are unique to those facing life after cancer and can varyover time,” says medical oncologistCrystal S. Denlinger. “Our goal is toprovide care that includes appropriatecancer surveillance and preventivemeasures, as well as attention to thepsychosocial aspects of survivorship,all of which are important to the healthof our growing survivor population.”

In the Center’s survivorship clinics,specially trained clinicians provideservices ranging from exams and diag-nostic work to counseling to addresssurvivors’ health needs and maximizetheir quality of life. They also workwith physicians to ensure patients’smooth transition from active treatment to survivorship.

The program is a collaborative effortamong clinicians, behavioral researchers, and laboratory scientists.“We work together,” Denlinger says,“to further survivorship research andbuild a clinical program that meets the needs of today’s cancer survivor.”

As director of nursing research, Andrea M. Barsevick works to improve life for cancer patients and survivors.


FACULTY

2807W2:2807W2 3/10/10 3:44 PM Page 23

STRENGTH IN WOMEN’S CANCERS

Newly diagnosed breast cancer patients can consultwith a team of specialists and develop a personalized treatment plan during a one-day visit to the BreastEvaluation Center, now part ofthe new Women’s Cancer Center. Building on Fox Chase’shistorical strength in women’scancers, the Women’s CancerCenter brings research, treatment, and prevention programs for breast and gynecologic cancers togetherunder one roof.

Margaret Mauran Zuccotti knows what ittakes to run a marathon. Strength.

Energy. Endurance. The avid athlete mustered all those attributes when she wasdiagnosed with stage IV inflammatorybreast cancer—an advanced, aggressiveform of the disease—at 37. She knew thatfighting the cancer would not be a sprint,but a new kind of marathon.

The mother of three young children, Zuccotti was prepared to go the distance totackle her illness; as it turned out, she didn’t have to go far from her home in thePhiladelphia suburbs. Physicians in her family, both on staff at a New York City-based comprehensive cancer center, recommended Fox Chase.

When she met medical oncologist Lori J.Goldstein, director of the Breast EvaluationCenter, Zuccotti already knew the fear anddoubt that can accompany a cancer diagnosis. And there was more grim newsto come. Tests showed her cancer to be afast-growing type that already had spreadto her liver, and possibly her skull. Goldsteindeveloped a treatment plan that includedseven months of chemotherapy. “It soundedlike an awfully long time,” Zuccoti recalls. “I found myself wondering ‘What does myfuture look like?’ ”

Goldstein and the other members of hertreatment team helped her see past thefear, Zuccotti says: “They reinforced thatI was in the right place, doing the right

thing, and helped me realize I would not bewaging this battle alone.”

One year after her diagnosis, thechemotherapy was proved successful: Follow-up tests detected no cancer in herbody. Zuccotti faced a decision. Togetherwith her team, she elected to undergo amastectomy to reduce the chance of recurrence. “My husband and I believe thatif and when my cancer comes back, we’llonly feel comfortable if we know we havedone everything to combat it,” she says.

Zuccotti calls Fox Chase “the perfect place”for her ongoing care. “As a stage IV breastcancer patient, I am well aware that I will be in treatment for the rest of my life,” shesays. “I’ve learned to accept my status as a long-term patient largely because of thishospital. Its doctors and staff have givenme the confidence to believe I can overcomemy challenge.”

For now, Zuccotti keeps running—and skiing, and playing lacrosse, and saltwaterfly-fishing. Competing in Philadelphia’sSusan G. Komen Race for the Cure in 2008and 2009, she was the first runner in thesurvivors’ division to cross the finish line—two years in a row.

She figures she has miles to go.

Margaret Zuccotti has put miles betweenherself and a diagnosis of advanced breast cancer.


2807W2:2807W2 3/10/10 3:44 PM Page 24

STAYINGON

TRACK

PATIENT

2807W2:2807W2 3/10/10 3:44 PM Page 25

CAUSEAND

EFFECT

2807W2:2807W2 3/10/10 3:45 PM Page 26


At the beginning of his career, immunol-ogist David L. Wiest had little interest

in doing clinically oriented research. Heplanned to focus on purely basic science—laboratory work that investigates funda-mental concepts and is more concernedwith advancing knowledge than creatingimmediately useful tools. But to get to hislab during his postdoctoral fellowship at theNational Institutes of Health, Wiest had towalk past pediatric cancer patients, manyof them in wheelchairs, their hair gone,their bodies ravaged. It was an experiencethat touched him deeply.

“That’s hard to look at and not bechanged,” he says. “After experiencing thattime and time and time again, the seedswere planted that made me want to do research that would benefit patients in amore direct way.”

During his 15 years as a Fox Chase researcher, Wiest has combined his love ofbasic science with his desire to have a positive impact on cancer patients. As co-leader of the Blood Cell Developmentand Cancer Keystone Program, he spearheads efforts to identify the genesmost important to the development ofblood cells—knowledge that could providephysicians with powerful tools in the fightagainst blood cancers, which are caused by genetic mutations.

Two tumors could look identical under amicroscope, Wiest explains, but if they aregenetically different, they might respond differently to treatment. “By determiningwhether there are differences in the partic-ular sets of genes tumors express, we canbetter arm the clinician with a strategy tocombat each tumor,” he says. “We start byasking whether genetic differences canhelp us understand how that cancer isgoing to respond to therapy. Then we ask,can that gene be targeted therapeutically?Does it code for an enzyme that we can target with a drug or possibly a moleculethat the immune system can be harnessedto attack?” An example of the latter, henotes, is the therapeutic antibody rituximab,which is effective in treating particularblood cancers with few side effects.

Wiest notes that the Keystone program,which brings together researchers andphysicians, bridges Fox Chase’s strengths in laboratory-based science and clinical expertise. In effect, the program givestranslational impact to the work of basic researchers.

“As scientists, we publish papers in journalsdescribing our new findings, and that’s greatbecause it pushes our field forward,” hesays. “But at some point, I wanted to knowthat what I was doing would have a lastingimpact, that it would really help people.”

THE TEAM:The Keystone Program

The Blood Cell Development and Cancer Keystone Program is one ofseveral Keystone programs at FoxChase whose interdisciplinary approach links bench scientists with clinicians in the pursuit of key cancerquestions. Molecular geneticist Jennifer Rhodes, an investigator in theblood cell program, says the Keystonesdemonstrate Fox Chase’s expertise inusing advances in basic science todrive the development of new diagnostic and therapeutic tools.

“A lot of places will say, yes, we have agreat hospital, we have great re-searchers, and we have the potentialto take what’s going on in the lab andput it in the clinic, but the Keystoneprograms help fund projects to reallymake that happen,” says Rhodes, whostudies the development of blood cells in zebrafish, which have the sametype of blood cells as humans.

The Blood Cell Development and Cancer Keystone Program identifiesthe genes essential for blood precursorcells to give rise to the many distinctblood cell types, a critical step towardunderstanding blood cancers and improving the treatment of patientswith leukemias and lymphomas. The other Keystone programs are in personalized risk and prevention, epigenetics and progenitor cells, personalized kidney cancer therapy,and head and neck cancer.

Scientist David Wiest wants his research on blood-cancer genetics to have a positiveimpact on patients.


FACULTY

2807W2:2807W2 3/10/10 3:45 PM Page 27

2807W2:2807W2 3/10/10 3:45 PM Page 28

THE YEARIN REVIEW

H I G H L I G H T S O F 2 0 0 9

“What makes Fox Chase unique, I believe, is the sense of a common missionamong all its employees. In a cancer center that sees many patients each day, we are constantly reminded of our singular emphasis.”

Glenn F. Rall, Immunologist

2807W2:2807W2 3/10/10 3:45 PM Page 29


The new Women’s Cancer Center bringsevery aspect of cancer care for women,from risk assessment and prevention toactual treatment and support for survivors,together under one roof. Opened in August, the center aims to provide notonly leading-edge treatment, but alsowellness resources and a supportive, nurturing environment.

“The idea is to treat the whole woman,not just the disease,” explains directorRobert A. Burger, an ovarian cancer specialist. “Cancer demands clinical attention, of course, but because cancerisn’t all of who the patient is, it won’t be the sole focus of her care.”

The center is distinctive in its comprehensiveapproach: Despite commonalities betweenbreast and ovarian cancer, most cancercenters treat them separately. Fox Chaseis thought to be the first National Cancer Institute-designated cancer centerto unify its research and treatment approaches in an entity that addressesthe full spectrum of women’s cancers.

The center builds on Fox Chase’s historicalstrength in women’s cancers. Among otherdistinctions, it is one of only five institutionsin the country to receive a prestigiousNational Cancer Institute-sponsored grantfor a Specialized Program of ResearchExcellence, or SPORE, in the prevention,diagnosis, and treatment of ovarian cancer.

Women's Cancer Center Treats ‘Whole Woman’ Satellite Facility Broadens Accessto Radiation Treatment More patients now have convenient access to Fox Chase’s world-class radi-ation therapy, thanks to a facility thatopened in July. Fox Chase Cancer Center Buckingham, the Center’s firstsatellite radiation therapy facility, is located about 20 miles north of themain Fox Chase campus in Philadelphia.

The facility offers the latest in radiationtechnology, including a CyberKnife® Robotic Radiosurgery System. (Formore about the Buckingham facility andits director, Shelly Hayes, see page 8.)

The Institute for Personalized Medicine,launched in May, seeks to leave the “onesize fits all” approach to cancer treatment behind in favor of a more customizedmethod. Using leading-edge technologyto expand the understanding of cancergenetics, the institute aims to matchemerging, targeted drug therapies to theunique genetic profiles of individual patient tumors on a much larger scalethan previously possible.

“This initiative will significantly expandour understanding of cancer at the individual and genomic level,” says institute director Biao Luo. “We will then

use that comprehensive knowledge todevelop personalized cancer therapies.

“Personalized medicine has been talkedabout for some time, but now we are at astage where we can develop personalizedtherapies in a systematic way, thanks tobreakthroughs in areas like DNA sequencing technology.”

Fox Chase is well-suited to pursue such an approach. The Center long ago earneda reputation for its expertise in cancergenetics, and its already substantialbiosample repository provides a wealth ofgenetic information to build on.

Institute Takes ‘Personal Approach’ to Treatment

Fox Chase Recognized as Centerfor Complex and Rare CancersThe Blue Cross and Blue Shield companies named Fox Chase a BlueDistinction Center for Complex andRare Cancers. The designationrecognizes the institutions offering thebest practices and highest standards invarious medical specialties.

The distinction recognizes the Centerfor providing high-quality patient as-sessment and treatment planning, inpa-tient care, and major surgical treatment,all delivered by teams with expertiseand training in complex and rare cancers.Fox Chase earned the designation forsoft tissue sarcoma and esophageal,pancreatic, gastric, rectal, bladder, thyroid, and head and neck cancers.

THE YEAR IN REVIEWNEWS IN BRIEF

2807W2:2807W2 3/10/10 3:45 PM Page 30

Program in Head and Neck Cancer Added to Keystone Roster


Nursing Department Sets Recordwith National Award For the third time in a row, Fox Chase’snursing department was awarded Magnet status, the nation’s highestrecognition for nursing excellence andpatient care.

Fox Chase is the first acute-care hospitalin Pennsylvania and the first specialtyhospital in the country to receive Magnetstatus. The Magnet program recognizesexcellence in areas including themanagement philosophy and practicesof nursing services; adherence tostandards for improving patient care;and attention to the cultural and ethnicdiversity of patients and their significantothers. Research has shown patients atMagnet hospitals to have better outcomes.

▲

Marshall Elected Board Chairman Della Penna Becomes Vice ChairmanDavid G. Marshall took office as chairmanof the Fox Chase board of directors in

February. A boardmember since 1994,Marshall succeededWilliam J. Avery.

Marshall is chairmanand chief executive officer of Amerimar

Realty Company, which he founded in 1987. Amerimar has commercial andresidential holdings throughout the country and is particularly well known for its successful development of The Rittenhouse, which includes condomini-ums and hotel and restaurant facilities, in Philadelphia.

Louis E. Della Penna Sr., a board membersince 2007, was tapped to succeedMarshall as a vice chairman.THE POWER OF PARTNERSHIP

Through the Fox Chase Cancer Center Partners program, the Center works with select community hospitals to help them provide the latest in cancer prevention,treatments, and diagnosis, as well as access to clinical trials. In 2009, 25 hospitalsparticipated in the program. For more information, visit www.fccc.edu/Partners.

A new program joined the Center’s inno-vative, team-based Keystone Programsfor Collaborative Discovery in August. The Keystone Program in Head and NeckCancer brings clinicians and scientists together to apply knowledge about thegenetics and biology of head and neckcancer to the treatment of the disease.

Head and neck cancer, which includescancers of the nasal cavity, mouth, throat,and voice box, affects more than 45,000people in the United States alone and has a survival rate of about 50 percent.

Fox Chase physicians are recognizedleaders in the field.

Like the other Keystone programs, theinitiative is led by an interdisciplinary team:medical oncologist Barbara Burtness, mole-cular biologist Erica A. Golemis, and headand neck surgeon John A. “Drew” Ridge.

The program was selected for Keystonestatus through a competitive externalpeer review process, making it eligible for at least $5 million in support over five years. Keystone programs are fundedprimarily through private philanthropy.

New Department Expands Prevention EffortsThe recently created department of clini-cal genetics takes Fox Chase’s pioneeringwork in cancer prevention a step further.

The department consolidates the clinicalcomponents of the Center’s existing risk assessment programs—which target people at heightened risk of breast, ovarian, gastrointestinal, prostate, andlung cancers, as well as melanoma—into a single comprehensive service that includes screening, genetic testing, counseling, and clinical intervention.

“We have gotten to the point as an institution where our risk assessmentprograms warrant a full-fledged clinicaldepartment, allowing us to expand theservices we can offer and, in time, thetypes of hereditary cancer disorders weassess,” says chairwoman Mary B. Daly.

The department’s staff of 30 includesphysicians, physician assistants, geneticcounselors, nurses, and health educators.

Federal Stimulus Funds Support Research Fox Chase research benefited from “stimulus funding” made available throughthe American Recovery and ReinvestmentAct. Among the initiatives funded:

Andrea M. Barsevick, director of nursingresearch, received a grant of nearly$218,000 in May to support research onquality-of-life outcomes in cancer treatment. Her project aims to define guidelines for managing the symptomsmany patients experience during treatment, such as fatigue, insomnia,pain, and depression.

The Center received an $8 million grantfrom the National Center for ResearchResources of the National Institutes of Health toward construction of a comparative medicine research facilitythat will support advanced research intothe biological processes underlying cancer,paving the way for the development ofnew treatments.

2807W2:2807W2 3/11/10 5:07 PM Page 31

Young Steps Down as Chancellor

After 20 years of distinguished serviceand leadership at Fox Chase, former

president Robert C.Young stepped downas chancellor in July.

At a ceremony commemorating the occasion, presidentand chief executive

officer Michael V. Seiden noted, “Dr. Younghas served as a compassionate and generous mentor and advisor as I haveworked to serve the Center during thesechallenging economic times and as wenavigate numerous transitions. I know Ispeak on behalf of many when I extendmy gratitude for his invaluable counsel.”

Young served as Fox Chase’s presidentfor 18 years, resigning in 2006 and takingup the role of chancellor. His legacy includes the creation of the first compre-hensive program of cancer prevention research, the Research Institute for Cancer Prevention.

Physicians Named ‘Top Docs’Twenty-nine Fox Chase physicians wereincluded in the eighth edition of America’sTop Doctors, issued in January. Featureddoctors are peer-nominated and screenedby physician-led research teams based

on criteria such as qualifica-tions, including education;professional reputation;hospital appointment; andexperience.

The guide represents thetop 1 percent of doctors in the nation, according to publisher Castle Connolly, a health-care research and informationcompany. The listing led to 27 of thephysicians also being featured in Philadelphia magazine’s annual “Top Doctors” issue, published in April.

Breast Cancer Specialist Heads DepartmentNoted breast cancer clinician and re-searcher Massimo Cristofanilli, formerly

of the University ofTexas M.D. Anderson Cancer Center, was appointed chairman ofthe department ofmedical oncology.

Cristofanilli, who joinedFox Chase in early 2010, specializes intreating patients with locally advanced,inflammatory, and metastatic breast cancer. He also focuses on translationalresearch, including the use of molecularlytargeted agents in imaging and therapeutics; breast cancer stem cells;the delivery of gene therapies for regionalrecurrences; and the role of circulatingtumor cells in inflammatory breast cancer.

Cristofanilli will play a leadership role inthe Women’s Cancer Center and thewomen’s cancer research program. Heholds the G. Morris Dorrance Jr. EndowedChair in Medical Oncology.

Longtime Fundraiser Joins CenterRobert G. Wilkens Jr., a veteran fundraiserfor cancer centers and other academicmedical institutions, became Fox Chase’s

new senior vice president and chief development officer in September. He succeeded Jill A.Marsteller.

Previously, Wilkens ledthe development programs at MemorialSloan-Kettering Cancer Center in NewYork City and the Ohio State University’sComprehensive Cancer Center–JamesCancer Hospital and Solove Research Institute. Most recently, he was executivedirector for development and philanthropy

for Memorial University Medical Center in Savannah, Georgia, where he workedclosely with the Curtis and Elizabeth Anderson Cancer Institute.

Radiation Oncologist Directs Satellite Facility Shelly B. Hayes joined Fox Chase in Julyas director of its new satellite radiationtreatment facility, Fox Chase Cancer Center Buckingham. Hayes, who did herresidency at Fox Chase, returned fromVirginia Radiation Oncology Associates inRichmond to take on the leadership role.Hayes has a particular interest in breast,gynecologic, prostate, and lung malig-nancies, as well as brain and spinal cordtumors. She earned her M.D. at TempleUniversity School of Medicine. (For moreinformation, see profile on page 8.)

Geneticist Leads InstituteMolecular geneticist Biao Luo, formerly of the Broad Institute of the MassachusettsInstitute of Technology and Harvard University, became director of the newInstitute for Personalized Medicine inSeptember. Luo also has an appointmentas research assistant professor in the cancer biology program. Luo earned aPh.D. in biological chemistry and molecu-lar pharmacology at Harvard in the laboratory of Jeffrey Sklar, followed by apostdoctoral fellowship at the WhiteheadInstitute for Biomedical Research in thelaboratory of Harvey Lodish.


THE YEAR IN REVIEWNEWS IN BRIEF

FACULTY AND STAFF: WELCOME TO NEW MEMBERS

2807W2:2807W2 3/10/10 3:45 PM Page 32

PROMOTIONS

Clinical CareJ. Robert Beck assumed the role of chiefmedical officer in June. He also continuesin his role as chief academic officer. “Aschief medical officer, Dr. Beck works withphysicians and nurses to improve the delivery of clinical care in both the inpatient and outpatient departments,”notes president and chief executive officer Michael V. Seiden. Beck also workswith clinical department chairs and senior administrative leaders to improveprocesses, quality, and safety in all patient-related areas.

Radiation OncologyEric M. Horwitz accepted the position ofchairman of the department of radiation

oncology in October. He had been servingas acting chairman, during which time he continued to distinguish himself as an expert in the management of localizedprostate cancer and the delivery ofbrachytherapy, as well as a productiveclinical researcher. Horwitz also holds theGerald E. Hanks Endowed Chair in Radiation Oncology.

Clinical GeneticsMary B. Daly was appointed chairwomanof the new department of clinical genetics.A medical oncologist, Daly focuses on the hereditary patterns of cancer andfounded one of the first cancer risk assessment programs in the country, theMargaret Dyson Family Risk Assessment

Program at Fox Chase. She directs theCenter’s Risk Assessment Program andholds the Timothy R. Talbot Jr. EndowedChair in Cancer Research.

Scientific Leadership Jonathan Chernoff assumed the dual positions of vice president and deputyscientific director, in which roles he worksclosely with senior vice president andchief scientific officer Jeff Boyd to directFox Chase’s scientific research. A molecu-lar oncologist, Chernoff focuses on thefactors that control cell growth andmovement, including oncogenes andtumor-suppressor genes. He also holds the Stanley P. Reimann Chair in OncologyResearch.

ACCOLADES

Physicians Assume National Leadership Positions• Eric M. Horwitz, chairman of radiation

oncology, became president of theAmerican Brachytherapy Society in thespring. Founded in 1973, the nonprofitsociety seeks to provide insight and research into the use of brachytherapy—radiation treatment given by placing radioactive material directly in or nearthe target or tumor—for malignant andbenign conditions.

• John A. “Drew” Ridge’s national leader-ship in head and neck cancer was recognized by the leading professionalsociety in the field. At the annual meet-ing of the American Head and Neck Society in May, the surgeon was elevatedto society president. The AmericanHead and Neck Society is the largest organization in North America dedicatedto the advancement of research and education in head and neck oncology.

American Cancer Society Recognizes Oncologist Medical oncologist Paul F. Engstrom, senior vice president of extramural research programs, was honored in November with the American Cancer Society’s Distinguished Service Award.

The award recognizes major achievementsand commitment in the cancer field. Anexpert in treating gastrointestinal cancers,Engstrom was honored for furthering theunderstanding and treatment of cancerthrough his clinical practice, research, andvolunteer work.

Nursing Researcher Honored by Academy Andrea M. Barsevick, director of nursingresearch, was selected to become a fellow of the American Academy of Nursing in November. Fellows are selected based on evidence of significantcontributions to nursing and health care.

“Fellowship in the Academy of Nursing isa top honor and major accomplishment,”notes Joanne Hambleton, vice presidentof nursing and patient services. “We are very pleased that Andrea was recognized for her contributions to thescience of symptom management forcancer patients and survivors.”

Geneticist Receives Research Award Geneticist Joseph R. Testa received the2009 Scientific Research Award from thePennsylvania Division, Southeast Region,of the American Cancer Society in October. The award recognizes his workin advancing the scientific understandingof how genetics and cell signaling under-pin cancer, particularly in the study ofAKT, a protein activated in many forms of cancer, including mesothelioma, an asbestos-related disease that often affects the lungs.


▲

2807W2:2807W2 3/10/10 3:45 PM Page 33

From the laboratory to the operating room, a sampling of the ways the Fox Chase team is expanding the understanding of cancer and improving treatments.


CLINICAL TRIALS

With approximately 225 clinical trials under way at any given time, Fox Chase offers access tothe latest lifesaving medical advances, sometimes years beforethey become widely available. For more information on the Center’s clinical trials, visitwww.fccc.edu/cancer/clinicalTrialsor call 1-888-FOX CHASE (1-888-369-2427).

THE YEAR IN REVIEWADVANCES IN SCIENCE & MEDICINE

Protein Shown to Support Aggressive Breast CancerFox Chase researchers have demonstratedthat a protein called NEDD9 may be required for some of the most aggressiveforms of breast cancer to grow—a findingthat could aid the development of improvedtools for diagnosing and treating the disease.

The study, published in October in CancerResearch, showed that reduced levels of NEDD9 in mice limit the appearance ofaggressive metastatic breast cancer.

“This was the first study to address thequestion of what happens in breast cancer if this protein isn’t around,” saysmolecular biologist Erica A. Golemis.“And the answer is that we see moremoderate cancer development, whichspeaks volumes about the role of theprotein in aggressive breast tumors.”

The protein could serve as a biomarker,or indicator, of aggressive forms of breastcancer, Golemis says. It also could provide the basis for the development of new drugs against the disease.

The Golemis laboratory identified NEDD9in 1996. In recent years, scientists worldwide have contributed to research showing how excess amounts of the pro-tein contribute to metastasis in cancersincluding melanoma, lung cancer, and atype of brain tumor called glioblastoma.

Funding for this research was provided by the National Cancer Institute, NationalInstitutes of Health, Israel Cancer Association, Stanley Abersur ResearchFoundation, Ben-Gurion University of theNegev, Pew Charitable Trusts, and theCommonwealth of Pennsylvania.

Experimental Breast Cancer DrugComes ‘Full Circle’ to Fox ChaseGiven the time it takes for scientific discoveries to travel from “bench” to “bedside,” laboratory researchers rarelyget to see their work affect patients—butthat’s exactly what happened over thesummer when Fox Chase became one ofjust two sites in the country to take partin a clinical trial of a unique drug shownto slow the growth of breast cancer.

Known as MM-111, the drug is based onthe molecule ALM, which was developedat Fox Chase in collaboration with researchers at the University of California,San Francisco. The two institutions part-nered with Merrimack PharmaceuticalsInc., which refined ALM for use as a drugin humans. The result was MM-111.

“It is a rare and wonderful thing to see aclinical trial begin at the place where theconcept underlying the drug was conceived,” notes medical oncologistCrystal S. Denlinger, who heads the MM-111 trial at Fox Chase.

MM-111 resembles an antibody—a proteinthe immune system uses to confront invading pathogens such as viruses orbacteria. However, unlike most antibod-ies, which bind to only one target at atime, MM-111—like ALM—attaches to twotargets simultaneously: the signaling proteins ErbB2 and ErbB3. The proteinsare believed to work in tandem on thesurface of many cancer cells, includingthose involved in head and neck cancerand drug-resistant breast cancer, to promote cancerous cell growth. The druglatches on to ErbB2 and, using that connection as a foothold, blocks ErbB3from transmitting molecular signals.

MM-111 is believed to be the first drug thatoperates in this way—as a “bispecific” antibody—to enter clinical development.

2807W2:2807W2 3/11/10 5:41 PM Page 34


‘Disorder’ within Proteins Is Anything But, Study FindsSections of proteins previously thoughtto be useless may have an unexpectedlyimportant biological role, providing certain proteins with a way to deactivatethemselves, according to structural biologist Heinrich Roder.

In the May issue of the journal Structure,Roder and his colleagues described thisphenomenon in a protein called NHREF1,which is crucial to cells’ ability to receivechemical signals. By comprehending theprotein’s structure, Roder believes, scientistswill better understand how the proteinfunctions—or malfunctions—in diseasessuch as breast cancer and cystic fibrosis.

“Here we have a molecule that serves animportant role in how cells function andsurvive, but it contains these puzzling‘junk’ sequences that don’t have any ap-parent purpose,” he says. “Our work sug-gests that this disorder is really a way ofcreating flexibility, allowing the protein tofunction as a molecular switch, a processthat goes wrong in certain diseases.”

NHREF1 serves as an adapter that allowsmolecular messages from outside the cellto trigger changes within it. The “disor-dered” sections of the protein allow it toflex and block its own active site as ameans of self-regulation. The discovery,made with the help of an innovative ap-plication of nuclear magnetic resonancespectroscopy—a technique that determinesa protein’s shape by measuring how individual atoms interact with an intensemagnetic field—was the first successfulattempt to determine the structure of thistype of protein.

Funding for this research was provided bythe National Cancer Institute, the National Institutes of Health, and theAmerican Cancer Society.

Genetic Marker May Predict EarlyOnset of Prostate CancerA preliminary Fox Chase study has identified a genetic marker associatedwith the early onset of prostate cancer in Caucasian men with a family history ofthe disease. The findings could help clinicians provide targeted screening tothose at highest risk.

Medical oncologist Veda N. Giri, director of prostate cancer risk assessment, presented the data in May at the annualmeeting of the American Society of Clinical Oncology.

“The genetic basis of prostate cancer isnot yet as well understood as it is forbreast, ovarian, and colon cancer,” Girisays. “Markers such as this one may helpclinicians distinguish men who are at riskfor earlier onset of disease at a pointwhen intensive screening can be discussed.Men who do not carry genetic markers ofrisk may not need such measures.”

More than half of all prostate cancer patients carry a particular “fusion gene,”a hybrid gene formed by the rearrange-ment of genetic information. Recently, researchers have pinpointed a specific allele, or form, of the gene that is morestrongly associated with prostate tumors.

To find out if the allele is clinically relevant in men at high risk for prostatecancer, Giri and her colleagues genotyped631 men with a family history of the disease who were enrolled in the risk assessment program. Overall, the alleledid not appear to contribute significantlyto disease in the 400 African Americanmen or 231 Caucasian men. The researchers then evaluated the marker in the 183 Caucasian men undergoingprostate cancer screening. They foundthe allele was associated with a 2.5-foldincreased risk of being diagnosed with thedisease and that men carrying the alleletended to develop the disease earlier.

Giri notes that the findings may also holdtrue for African American men, who areparticularly prone to prostate cancer.However, the study population was toosmall to test that theory. “This was a pilotstudy,” she says. “Our future research willinvestigate whether this association holdsup in a larger Caucasian population, andwe plan to collaborate with other institutions to test whether this marker isinformative in African American men.”

▲

2807W2:2807W2 3/11/10 5:42 PM Page 35

Surgeon Performs First SuccessfulPancreas Surgery Using RoboticTechnology In March, a Fox Chase physician performedthe world’s first successful minimally invasive distal pancreatectomy—the removal of part of the pancreas—using arobotic system that improves surgeons’control and precision.

The case constituted the first time theViKY® robotic compact laparoscopeholder—developed in France and testedon thousands of patients in Europe—wasused in a cancer case in the United States.

Minimally invasive surgery, which involvesonly small incisions, offers patients ashorter hospital stay, faster recovery, andless scarring than conventional open surgery. During such procedures, surgeonstypically use both hands to manipulatethe surgical tools and need an assistant tohandle the laparoscope—a thin, lightedtube equipped with a camera that allowsthe surgeon to view the surgical field.

The ViKY system “acts as an extra handduring surgery, giving me stability andsteadiness,” says Andrew A. Gumbs, thesurgeon who performed the procedure.With the ViKY system, the laparoscopemoves according to the surgeon’s orders,either through voice recognition orfootswitch control. Gumbs, who specializes in minimally invasive hepato-pancreatic and biliary, or HPB, surgery,performed the procedure on a 65-year-old man with two pancreatic cysts, one ofwhich was deemed potentially cancerous.

Gumbs, who joined Fox Chase in 2008,was the first American surgeon to com-plete a minimally invasive HPB fellowshipat the Institut Mutualiste Montsouris inParis, where the first published case of asingle-incision laparoscopic gallbladderremoval was performed using the ViKYsystem. He is responsible for bringing thesystem to Fox Chase and is training fellow surgeons in its use.


PARTICIPATE IN DISCOVERY

To learn more about Fox Chase research, including how to support research efforts, visitwww.fccc.edu/research. Information on charitable giving is also available by e-mailing [email protected] or calling 215-728-2745.

2807W2:2807W2 3/10/10 3:45 PM Page 36

THE YEAR IN REVIEWFOX CHASE AT A GLANCE

Financial Overview

OPERATING REVENUES OPERATING EXPENSES

Total Revenues: $329.6 million Total Expenses: $338.2 million *Data apply to new patients treated in 2008.

Types of Cancer Treated

■ Patient-care Revenue 74%■ Research Grants and Commercial Support 17%■ Fund-raising Support 4%■ Governmental Appropriation 3%■ Investment and Other Support 2%

■ Salaries and Benefits 56%■ Supply and Drug Costs 19%■ Purchased Services 13%■ Capital-related Costs 7%■ Other 5%

Patient Care

NEW PATIENTS 7,646

OUTPATIENT VISITS 77,003

TOTAL PATIENTS SEEN 32,577

106 years treating cancer patients 262 registered nurses

2,483 total employees 2 Nobel prizes earned by scientists

46 countries of origin of employees 8 operating rooms

Fox Chase by the Numbers

77,003

32,577

7,646


■ Prostate 16%■ Breast 13%■ Lung 12%■ Head and Neck 7%■ Kidney 7%■ Colorectal 6%

■ Bladder 5%■ Lymphoma 5%■ Skin 4%■ Pancreatic 3%■ Other 22%

2807W2:2807W2 3/11/10 6:58 PM Page 37

A MESSAGE FROM THE CHAIRMAN OF THE BOARD OF DIRECTORS

How do you express appreciation for expert, compassionate care?How do you make a contribution to medicine without going to medical school? How do you honor a community of researchers, physicians, and nurses who inspire you?

The more than 800 individuals and organizations listed on the following pages have answered these questions through their generous support of Fox Chase. Their giving reflects gratitude and appreciation—and something more: confidence in a vision of what ispossible with the right resources, and a personal commitment to the mission and valuesthat animate Fox Chase and its dedicated faculty and staff.

These special partners—patients, family members, and friends—constitute an important part of the Fox Chase team, and I am proud to join them in supporting the Center. Like so many, I have been personally affected by cancer: My mother and all five ofher sisters died of the disease. I am not in a position to find the cure, but I am determinedto do whatever I can to help Fox Chase do so. As donors, we are united in the commoncause of supporting uncommon excellence.

Included in the following pages are stories illustrating how gifts have made a difference atFox Chase and the meaningful ties that bind these donors to the Center. I know you’ll enjoyreading about the siblings who carry on their parents’ decades-long legacy of supportingcancer research; a patient who continues to demonstrate her abiding appreciation for thecare she and her parents received at Fox Chase more than a decade ago; and an advocatewho came to Fox Chase as a supportive husband and who has since become a championfor esophageal cancer research.

The common thread throughout these stories—and many more that I have been privilegedto hear—is a hopeful outlook on the future. What breakthroughs might the next gift makepossible? Where will today’s advances take us tomorrow? As donors, we all participate in this exciting cycle of discovery and hope. Few investments yield a return as deeply satisfying as extending, improving, and saving lives. A gift could hardly do more.

On behalf of the board of directors, I am inspired by and grateful to all of our donors forpartnering with Fox Chase in its effort to improve cancer medicine for all.

Sincerely,

DAVID G. MARSHALL


2807W2:2807W2 3/10/10 3:46 PM Page 38

FRIENDS& SUPPORTERS

“This is an extraordinary time of opportunity in cancer research. Answers arewithin reach of our talent, passion, and expertise. Our only limitation is in havingthe resources to realize our shared vision.”

Michael V. Seiden, President and Chief Executive Officer

2807W2:2807W2 3/10/10 3:46 PM Page 39

Carol Elfant

Coming Home

Carol Elfant remembers 1997 as a year ofhealth crises: She and her parents all

became patients at Fox Chase. Her motherwas diagnosed with lung cancer, while herfather, already being treated for prostatecancer, moved to Fox Chase when his condition worsened. Several months later,while caring for both of them, Carol herselfwas diagnosed with endometrial cancer.

“Among the three of us, we were inpatientson almost every floor,” she recalls. The silver lining, she says, was that “we knewwe were getting the best treatment possible;we felt cared for every step of the way.”

Elfant lost both her parents the followingyear. Just months later, she made her firstgift to Fox Chase, splitting her supportamong patient care, lung cancer research,and prostate cancer research. “Everyone atFox Chase is amazing—so dedicated and sosupportive,” she says. “I got so much fromthem, and I wanted to give back.”

Thirteen years later, Fox Chase remainsElfant’s philanthropic focus. Her annualgifts to the Center convey “the trust I havein Fox Chase,” she says, and she has expanded her support to include nursingdevelopment and education, as well asCoventry House, an apartment complexthat provides patients with affordablehousing during treatment.

“I have so many positive memories of FoxChase that I give as much as I can, wheneverI can,” she says. “Now when I come for myfollow-up appointments, I feel like I’m coming home.”

The memory of her parents, both of whom were Fox Chase patients, remainsstrong for donor Carol Elfant. Because of the care her family received, ‘I wantedto give back,’ says Elfant, herself a former patient.


2807W2:2807W2 3/10/10 3:46 PM Page 40


Fox Chase wishes to acknowledge the following donors for their generous support in 2009.Laurel Society—Founders’ Circle($500,000 and up)Edith J. HolgateBonnie & Peter McCausland

The McCausland FoundationCarolyn D. Galbraith PanicolaMargaret Dorrance Strawbridge

FoundationCarol & Kenneth E. WegLoralee & Alfred P. West Jr.

Laurel Society—Chairmen’s Circle($100,000–$499,999)Sharon & William J. Avery

Avery FoundationMargaret D. BarbarTherese CohnMargaret N. CulverCarol A. & Louis E. Della PennaEdith J. Holgate Family TrustMargot & Robert E. KeithThe James & Agnes Kim Foundation, Inc.Naomi P. & Philip E. LippincottMary Alice Malone

Roemer FoundationSandra G. & David G. MarshallLauren & Donald E. Morel Jr.Robert F. NovakChristine A. Poon & Michael TweedleNina G. & George E. Strawbridge Jr.Jane VillonRoy H. Woll

Laurel Society—Advocates’ Circle($20,000–$99,999)An Anonymous FriendElizabeth E. AretzLucy S. BinderRuth M. BleakleyAmy A. Pruitt & Andrew G. BodnarHelen T. BrownJoyce & Robert L. Byers Sr.

The Byers FoundationJudith T. CarpenterMary J. & John ConteChristine T. & Gordon O. DanserDietze Charitable FoundationG. Morris Dorrance Jr.Foundation For The CarolinasEsther G. & Robert A. FoxMarie E. FunkPenelope HarrisKay & Thomas W. HofmannMolly & Lawrence T. Hoyle Jr.Evelyne V. Johnson & Thomas G.

Paynter FoundationBarbara R. & Charles Kahn Jr.Jessie KartynEdwin M. Lavino FoundationWendy & Andrew L. Lewis IVEthel A. McCollaumRichard B. MillhamGordon G. NorcrossAnne M. Rorer

Sarah H. Wolfberg & Toby WolfbergBarbara M. & Robert C. Young

Laurel Society—Champions’ Circle($10,000–$19,999)Alice C. BassettSadie BernsteinLloyd & W. Thacher BrownVirginia W. DunnLinda & Philip GersonFrank R. GianforteCheryl & Scott HermanLynne & Harold A. HonickmanDavid KernerDaniel C. KubackiJudith & James F. Mitchell IIILouise Mauran NadlerFaith OtteryWenona & Raymond A. Paul Jr.The Rhode Island FoundationMary D. & Edward J. RoachEdward C. SchmittMary S. & John E. Snyder Jr.George H. TalbotSandra W. & Timothy C. WeckesserRose Weiss

Laurel Society—Guardians’ Circle($5,000–$9,999)Nancy J. & Armando AnidoAndrea M. Barsevick & Rudy SprinkleMaggie & Bob BeckBeier Family Foundation

Elinor M. & Ernest Beier Jr.Suzanne H. & Frank G. Binswanger Jr.John K. BinswangerThe Binswanger FoundationMary D. BorlandJane & Wayne L. Bromley Jr.Broughton FoundationEli Caplan

Julius H. Caplan Charity FoundationMarian C. DamianiMary & Gwilym C. Daniels Jr.The Drueding FoundationRita E. & Charles E. Dunleavy Jr.Linda FonnerGBH FoundationSaskia M. & C. Meade Geisel Jr.Dominic & Janet Genuardi Family

FoundationJanet & Dominic Genuardi Jr.Gianforte Family Charitable TrustHelen & John S. GradyElizabeth Kapnek GrenaldBarbara L. GrozinskiBeverly & Gordon HattersleyHollenbach Family FundHerbert S. & Eleanore L. Howard

Charitable FoundationMary F. KligerWalter KnetlarJill A. MarstellerPamela Minford Charitable Foundation

Shirley & Gordon V. MoyerDoreen H. PayntonJane G. PepperPKG FoundationLinda & Paul RichardsonKathy & Michael RozanskiMarilyn & Donald E. SchmittMichael V. SeidenRenee & Dennick M. W. SkeelsIsabella P. Spratt FundJudy StankewizElaine & David T. SykesLynn & Raymond C. WarneckWalter Williams

Laurel Society—Patrons’ Circle ($2,500–$4,999) John T. AbramElizabeth AndresonBeverly & David B. ArshtJean & Baruch S. BlumbergKathleen & Anthony BoccellaAdele P. BovaRuth E. BowmanDeborah & Edwin R. BoyntonWendy & Morton R. BranzburgJenne K. BritellElinor & James M. Buck IIITimothy CanizLeo ChoiAnthony CianfraniKathleen CitrinoTess Clayton Charitable FoundationSuzanne ColligasBenjamin F. Delong Leslie S. & Mark DeNinoArline & Ira R. DolichMarvin B. DrendallEden Charitable FoundationMarsha & George S. FaassFrank FeinThomas P. FoleyMarci & Robert HackelJessica HartmanRachael & Josh HirshenhornJennifer M. HouckFrances E. & Raymond C. InghamMary Ann & Matthew KonopkaSusan & William G. LittleCatherine & Lawrence McDevittMichael D. MulcahyMadeline & William R. ParkerBlanche & Ira Rosenblum FoundationSheila RusserThe Samantha Fund Community

Foundation of NJKathryn SchulbergBrian ShawSanford ShkolnikAnn & David H. SingerNicholas SkimboAlice H. SmithRobin & John C. SpurlinoSusan H. & Richard Tofani

Louise & Thomas R. TrittonDaniele & Guy VeroliGloria VisnovEugene WaitersHarriet & Louis M. WeinerWilliam WeisserRonald L. WolfJ. Terry Ziegler

Laurel Society—Partners’ Circle($1,000–$2,499)Patricia AdamsLisa & Stanley J. AltmanSusan E. Andrejev &

Joseph B. HoffardDenise & James M. ArmstrongJeanne ArmstrongMyra J. & E. Boyd AsplundhRobert D. AustinRegina F. AutieriTheodore J. AvilSuzanne & Richard BalbirerJohn F. Bauder Jr.Edward C. BayerTheresa & Jeffrey P. BealeLorraine S. & Robert C. BellNina BeyerTerry & Dan BlomgrenJudith A. BoiceMarian & Arnold G. BowlesMary BoyleGeorge P. BridegumCynthia J. BriolaJeffrey BrownCecile L. & Mark BurgertTheodore ButeraDonald R. CaldwellMary Kathryn CampbellGeraldine & William G. CampbellJoan E. CanfieldChristine CardamoneEva C. CareyPatrick CassillyPatricia & Robert CerwinVeda & Leopold A. CesnaKathryn E. & Jonathan M. ChesshireKenneth ColePaul C. ConeysRichard M. Connolly Sr.Norton CooperMargaret & Jay K. CristMaureen E. & J. Russell Cullen Jr.Nicola CulmoKathleen A. D’AmicoKathy & Robert F. DeutschJoan & Barry DickinsonValerie J. & Ronald C. DicksonKaren DidonatoMabel & James E. DillerRichard DobrowolskiMartin DolanLinda B. & Eric M. DovmanSandi DraperTobe & Arnold S. Dresner

▲

FRIENDS & SUPPORTERS

2807W2:2807W2 3/10/10 3:46 PM Page 41


Lowell H. DubrowMary Sue & John R. DurantSteven A. EllersGloria & Bruce D. Ellsworth Jr.Nancy B. EnglishJanet & Paul F. EngstromAgnes & Edward ErnestDwight E. EvansErich A. EvertsMichael B. FarleyThe Feldman Family FoundationStephen FeuchterEmma & Charles V. FisherPatrick FlanneryAmber L. & David FlynnCameron FowlerThe Fox FoundationConnie & Philip E. FoxDonna L. FrancoAn Anonymous FriendSue E. FruchtenichtJohn Gailey IIIJames P. GallagherJohn GiannoneElizabeth & Steven R. GilbertJames Gillespie Jr.Mark GlemserDiana Keat & Edward A. GlickmanDawn Goodelk & B. Reuben AuspitzBrady L. GreenTina & James C. GreenwoodMary T. GriffithsNancy L. Grove & Jim BunderlaMary E. HallowellOleh HaluszkaNancy C. & James W. HarperShelley Wolf Harris & Steven P. HarrisGilbert C. HeathCharles L. HeatonHoward E. HecklerAlice C. HennessyEdmund W. HennessyVirginia HigginsKathy P. HindmanMitchell HinesElissa D. & George HirschhornJerry D. HolbrookChrista L. HopkinsMarilyn Y. HosangSteven D. HowardLiezel H. & Anthony T. HuberCarol A. & Francis O. HucksElizabeth & John HughesMrs. David A. HungerfordAngelo IacovellaDoralice & James M. HintonLisa KahudicHarini KapadiaNancy & Sol S. KashoffGladys S. KellyAnne D. & Kevin J. KellySherry A. & Daniel B. KelmanJonathan D. KingerySallie & Berton E. KormanRuth & Lester H. KrawitzPatricia F. Kugler

Lee Ann & Richard F. LambJennifer V. M. & Noel LangloisPam LavroffMary E. LeashMarie T. LeithauserAnna LesserFengsheng LiThe Seymour V. & Zena Lipkowitz

Foundation, Inc.Karlyn LoebVito LoguidiceLinda L. LucciJohn V. LynchHelen T. MadeiraJacob H. MaltaManat FoundationAngeline & Gerald J. MannaAlan W. MargolisLianne C. & Carl D. MarottaVirginia R. MartinThomas McCoolRosa & Ellice McDonald Jr.Stephen McKenna & Curran J. McKennaCynthia & James McKevittMichael J. McPaulDonna McQuillenDavid R. McShaneDonna Marie McTagueDorothy & John E. MeggittStewart C. MillmanJ. William Mills IIIRaymond MirraNona & William H. MorganMonica Morrow & V. Craig JordanTimothy G. MullarkeyClaire & Thomas J. MulvaneyCindy NgJeff NortonMarie Deratto & Alan R. OffermannMichele R. O’KeefeHeather O’NeillOpdyke Inc.Rose OringerFred OttMr. Anthony V. PagnottoJean-Loup M. Parier &

Francoise ParierNorman PartonKathleen M. & Jim PaskillPradeep R. PatelMarsha & Jeffrey E. PerelmanPatricia L. PerfectStephen PeroutkaPincus Family FoundationGeraldine A. & David N. PincusPreeti PintoPeggy & Clark D. PitcairnLachlan PitcairnLinda E. & Alan PollackSusan PoundEstelle & Stuart E. PriceDemetrios G. ProiosNancy & Stephen J. RauscherMagda & Robert RebutatoMartin M. Reed Jr.Lisa A. Reese

Carole A. & Lawrence G. ReilleyJohn W. Rich Sr.Antonia M. & Steven L. RichmanSylvia RiebmanMaureen & John RizzoRichard C. Roden

Millie & Jules Roden Endowed Research Fund

Susan K. & Robert C. RoethkeAgnes E. RomanoElizabeth A. & Gerald B. RorerJill S. & Norman G. Rosenblum

Hedda L. Komins Fund for Breast Cancer Research

Julia L. RosenwaldCorinne R. RoxbyKathleen A. & Charles E. RyanCarol SaginDonna & Lucio SalvucciPhyllis & James E. SaultzThe Savidge Family FundEllen M. ScholleSusan K. & Howard SchrenkPatricia B. & Harris A. SchwartzMarilyn & Alan R. SchwedelBarbara & Dan ScriboniLeeann ShiveleySandra & Robert T. SimsLorrie SmytheElsie L. SpiroJohn Spolitback Jr.Peggy C. & Ralph H. StarkeyDerrick L. StatonPauline & Harold H. SteinStolzman & CompanyStefanie StoyanovHenry StuebnerMona & Alton I. SutnickRebecca M. & Clifford H. SwainClaire & Raymond TatlowChristine TaylorDeedee TaylorMary & Augustus J. TornettaDorothy TroianoRebecca R. & Barry L. TroupTrustorff Family FoundationNatalie & Peter F. Vaccaro IIIDana & John ValentiKimberly G. WalkerMichael WallDerek WaltersMargot I. & Franklin H. WestFrancine & Junius E. WhiteTerri & James WhiteVera & John M. WilsonBarbara WirickKristin Wolcott-EdwardsJan & Albert WolfRoni & Daniel F. WolfsonJohnina C. & William S. Woods Jr.Edward G. WostairKathleen E. & Anthony E. YarmolykKaren & Bruce E. Young

Annual Donors($500–$999)A&R Charitable Foundation Inc.Joseph E. AbbottLauren Weisman & Brian D. AlmondKaren D. & Marion A. Alston Jr.Esther F. Ambrogi HurleySheila AmrheinColleen ArmstrongElfie M. & Alvin AshCatherine AvalloneSusan K. BabyakSarah Bailey & Meredith LightstoneMyra & John M. Ballinger Jr.William Barclay Jr.Dennis BarnesGloria & Donald J. BarnesSarah W. BarrScott H. BarrLorraine C. BasaraMarcia BattistaTom J. BattleWilliam BeaverRaymond J. BecklerRobert J. BennettKatherine L. BergethonJudith BernsteinGeorge BeschenCarol A. BesselJohn G. S. BillingsleyElin B. BinderNeena F. & Ronald G. BirchJoe N. Blango Jr.Jayne & Michael BlasekJoanne K. & Arthur BluethenthalSandra Pat BollingerElizabeth S. BourquinSusan & Wendell P. Bowman Jr.C. BoydMary E. & Jeffrey T. BretzJeanne Brisbin SmithMichelle A. & Scott BrowerBurnell A. Brown Jr.Caroline & Henry I. Brown IIIThe Brungard FamilyRichard BurkholderKaren A. & Douglas G. BurtSuzanne J. BuzzardSusan M. & Bruce W. CampbellJanice E. & Robert A. CannizzoJames A. CannonAnne & Andrew B. CantorCarole S. & Anthony C. Capaldi Sr.Carl A. CarlsonJason CarpenterJohn J. CashmereNicholas CavallaroArthur J. Centrella Jude CharlesTina M. ChesterAna ChilesTony ChiricoEunice & Charles J. ClarkeEdward B. ClayJohn ClearyMichael Clothier

▲

continued on page 45

FRIENDS & SUPPORTERS continued from page 41

2807W2:2807W2 3/10/10 3:46 PM Page 42

Frank Gianforte

A Husband’s Story

Frank Gianforte supports esophagealcancer research at Fox Chase for two

important reasons: He feels he’s continuingthe legacy of his wife Dale, who died of arare form of the disease in 2008, and—appreciating the fact that progress in science is “incremental”—he wants to play arole in advancing the understanding of thedisease and improving treatment options.

“This is exactly what Dale would havewanted,” Gianforte says. “To know that insome small way, we are having an impacton other people’s lives.”

The Dale Douglass Gianforte Fund forEsophageal Cancer—established with giftsfrom Dale and Frank, as well as friends andfamily members—provided seed money forresearch into IGF-1R, a cellular receptor thathas been found to stimulate esophagealcancer growth. Fox Chase researchers areinvestigating the anti-cancer effects of an IGF-1R inhibitor when administered in combination with chemotherapy for patients with metastatic esophageal cancer.

“We were always impressed with the op-portunities at Fox Chase for access to newtreatments and clinical trials—that’s simplynot possible without investing in research,”Gianforte says.

He notes that while the life expectancy forpeople diagnosed with the form ofesophageal cancer that his wife had is onlya few months, “we had Dale for 22 months.We like to think something was learnedfrom her cancer.”

Frank Gianforte, whose wife Dale died of esophageal cancer, is gratified by the knowledge that her legacy could save someone else’s life. The Dale Douglass GianforteFund for Esophageal Cancer supports research on the disease, which has a low survival rate.


2807W2:2807W2 3/10/10 3:46 PM Page 43


The Bernard A. and Rebecca S. Bernard Foundation

Thinking Beyond Themselves

B ill Bernard still remembers his grand-mother’s battle with breast cancer in

the early 1940s, which culminated with herdeath at age 47. That experience inspiredhis father, Bernard A. “Bernie” Bernard, toestablish a foundation that has supportedFox Chase research for decades. “My fatherwanted to help all people through research,”Bill recalls. “He always thought beyond the moment and beyond himself.”

Since the senior Bernard’s death in 1988, thefoundation has been led by Bill and his sisters,Estelle Solomon and Marlyn Bernstein. Bill’swife Joan also shares a connection to FoxChase: The Center successfully treated hermother for metastatic melanoma more than20 years ago.

The family is excited that research theyhave helped to support may prove a boonto cancer care. A molecule developed by

researcher Gregory P. Adams and his teamin the Bernard A. & Rebecca S. Bernard Laboratory, established with a leadershipgift in 1990, may provide a means of slowing cancer’s spread and deliveringmore aggressive drugs directly to cancercells. The molecule, nicknamed “ALM,” hasbeen shown to halt the growth of breastcancer cells in laboratory tests and mayalso provide a means of early detection. The findings were published in the BritishJournal of Cancer in November 2008. Anexperimental drug based on the molecule is now in clinical trials. (See story on page 34.)

“We feel strongly about Fox Chase and itsresearch,” Estelle says. “It’s making a difference for the future, and that’s one ofthe most meaningful things we can do.”

Overseen by Bernard A. and Rebecca S. Bernard, researcherGreg Adams peruses the results ofa recent study. Funding from theBernards’ foundation supportedhis laboratory’s development of a molecule that shows promisein diagnosing and slowing breast cancer.

2807W2:2807W2 3/11/10 7:03 PM Page 44


Joann M. CoatesMichelle D. CoburnSandra A. & Frank ColelliJeannie M. ColomboSusan ColucciFlora & Tomas F. ContrerasDebbie R. CooperFredi & Harry S. CooperAdrienne CortiCosta Charitable TrustEugene CoughlinEmma G. CunninghamWayne CurryJayne CusterStephen L. Cybok Jr.Drew R. DalyRoseann & Gregory J. D’AngeloRena & John A. DarazsdiMichele A. D’AulerioMichael A. DeGeorgeDominic J. DeSimoneLinda & Robert DevlinLora Jo & Russell DickhartJune & George DiDomizioPhyllis & Michael J. DiMeoKimberly A. DiPierroBeth DiPreteEllen L. & William F. DohmenElizabeth A. & Christopher DoleShari & Neil DolinskyAlfred J. DoodyJoseph M. DriverPatrick M. DriverBarbara & Paul R. DuganDeborah F. & Robert E. DunnCarol E. & Wayne E. DuttCarol ElfantDan EspenCheryl K. & Robert C. FaixCandace & Philip F. N. FanningJames FaustOlga FeldfuksPatrick M. FelixFrances FettnerF. Ray FinleyAmy R. & Jon S. FisherDavid FisherJudith J. FisherKatrina N. FisherGenevieve P. & Jack FlanaganJudith H. & Stephen D. FlanaganDiane N. FloodLynne FriedmanJoseph W. Fullem Jr.June & Charles L. FultonJohn GaudioBarbara GenuardiSuzy & Gregg GilbertAnne M. & Charles M. GingrichJoan F. & Nicholas J. GiorgioSusan GlecknerDorreen & Todd GlefandBarry GluckCecilia A. & Andrew GodwinJudith Goldberg & Lauren GoldbergAdele & Alfred E. Goldman

William Goldman FoundationRuth & Robert J. GoldstonWilliam A. GoodsonBernadette M. & Andrew J. GordonAnne B. & William E. GouakChristopher GradelDavid E. GreedIrene & Donald GreenhallAnna M. & Stanton R. GrellerJohn J. GricoskiRita S. & Charles GriffinOlga GroshevaJulie & Alan GubernickLaura & Donald E. HagerEvelyn HagermanSuzanne HamiltonDaniel A. HammondBeth C. HanssensDoris L. HarperBeverly Harrison & Sean P. LakinJill HarrisonAndrea HartleyJulie Hattrup & Liz HattrupJames P. HayesRobert R. HeaneyHolly HeckathorneMaryanne & Joseph F. Hediger Jr.Gretel & Walter HellendallRuth K. & Alvin C. HermanRhoda G. & Bernard B. HermanEileen M. & Francis HeronColleen M. HinckenRobert C. HinckleJohn HirshbergerJoan M. & Thomas A. HolmesKatherine V. HorneBarbara & Randall HoveChia HsiungElaine D. & William J. Hubing IIICatherine HughesLaura HughesAnna A. & Norman W. HunsbergerLori HunterRuth L. HuysmanGeorge H. IrwinAn Anonymous FriendPaul IvansDavid G. IvesBonnie A. Jacobs & Jack M. WeinerF. Warren JacobyKaren E. & Bernard C. JadachKim V. & Kenneth JankowitzMarie-Pierre Jdanoff CroweJudith JesiolowskiGlenda C. & John R. JesterYingbiao JiAnne JohnsonPricilla JohoBethel & James F. JungeSuzanne & Jeffrey C. KahnEdna B. Foa-Kahn & Charles KahnRichard P. Kahn FoundationGary KahudicEunice P. & Stanley G. KalbachRuth KamenJulius M. Kantor

Barbara & Bernard KaplanWendy & Theodore H. Kapnek IIIDonna & Jay M. KarfunkleDavid H. Keller Jr.Doris R. KellmerThomas KetterBarbara & H. Wayne KeyserJohn R. KibblehouseRichard KilleenBobby Ellen KimbelPatricia KindMary-Beth C. KingJohn KirbyJosephine KleinJeanette KlineDiane K. & Dwight D. KlothGeorgia B. & Richard KoenigMichelle KomrausPatricia C. & David W. KoonsBernard M. KosowskiRonda M. & Alan KotzenKrakauer Beneficial SocietySevi R. & Melvin E. Krigel FamilyLori Ann KroppRichard P. KubackiKimberly & Michael KushnerRita KuslerRhonda E. KutzikMark LangAnna & Ernest LarenzMary A. LaRueLynn LawrenceMartha J. & R. Donald LeedyLois Lehman-McKeemanStephanie K. LehrbachMatt LevineIrene A. & Ellis J. LevittErin N. LiberatoreJennifer A. LipmanGregory LitzingerRobert LambertH. Eleanor LodholzHelen L. & Stephen LoidlThe Lopes FamilyCharles C. LovellIra LubertLili Chen & Charlie MaRobert MacKenzieShirley & Arnold MaddreyThe Malfer FoundationS. Victor MaltaJoseph M. MammarellaMary & Ellis ManningHelen Marakis & FamilyMaripaz MarambaAnne Marble & Thomas A. CaramanicoHarold H. MarcusAnne MariucciRaymond MartinMary Jane & Clifford H. Matson Jr.Valerie A. & Randy S. MaugleJason T. MauroTammy L. & David Maver IVJody L. MaxminIrving May & Edith H. May FoundationJoseph N. McAllister

Keith M. McCarthyGeorge P. McCartyKenneth W. McCordEllen C. & Brian D. McCormickJoseph J. McCourtChristine A. & William McDonnellTarabeth & Kevin McFaddenThe Family of Mona McLeanNancy S. & Michael B. McLellandDaniel McManusKathleen E. & John J. McShaneMildred C. & Robert T. McShaneMary E. McVeighBrenda A. MerrillRick MessnerMichael MinannoSeda MirabileAnita P. MocorroGerrianne MonteiroPaul S. MooreCourtney & Patrick MoorheadKenneth J. MoranHelen D. MorganKathleen & Francis X. MorrisSelma Mosko Winter &

The Mosko FamilyGeorgette M. MostKara & Jeffrey MulkuskyDeborah MullenLinda J. MullenRichard H. MulliganPatricia NataleAnna P. O’ConnellKatherine A. OdorowKristine O’HaraConnie OlingerJean I. & Steven J. OlsenSusan & James V. O’Rourke Jr.Michael W. OwenMichael OwensHeidi & Scot D. PannepackerJohn G. Paretti IIAris PaslesJean V. PerrottLillian PessilloAmedeo PetrongoloPhilipson Family Charitable FundJanna PierceNorma M. & Richard R. PieritzMichael PowerMark RameyGeorge RamseyJudith & Isidore RicciutiPatricia A. & Daniel M. RiceBenjamin A. RichmanMarcia J. RichterChris RobertsonPeter RodriguezMiriam I. RomanBrian C. RudiBrian RussoVicki & Michael R. RussoHenry F. RyderRuth E. SaccoSusan A. & William F. SalduttiFrank Samecki


▲

2807W2:2807W2 3/10/10 3:46 PM Page 45


Julie SantiagoJulie & Benjamin SavitchDapphne SawyerBeth SchindeleGrace V. SchmidtJessie Schol & Sarah ScholPatricia & Richard SchrammThe Schraut FamilyDavid SchwartzDeborah G. SciasciaElaine & Ronald SeilerJames J. SenderlingSharon & John SharoAndy ShawMary & Antony ShawTavis ShawAgnes M. SheehanDorothy H. & Wilbur K. ShoemakerIrene M. ShoffnerDeborah & Giovanni SicilianoDorothy E. SiebertRuth SiffordBetty & Steven SilkunasEileen SimzakFrank SinkovitzVeronica J. & Charles W. SitarskiDonald SmithE. Pearl SmithJoan T. & Norman H. SmithAlice M. SnyderCynthia & Howard SolganickLouise A. SonnenbergGregory J. SossonJan H. & Andrew SouicerAndrew SpeakerHarvey G. StengelSteven J. StorerErwin StrawMargaret & Edward B. StreckerDonna J. StrohmAn Anonymous FriendCarl SutterRobert G. SykesKarin B. Takiff & John B. FrankGeorge H. TalbotJennifer TanayJames TerpeningNelly B. & Hans ThalheimerSuzanne ThomasMary T. & John E. ThrowerPatrick R. ToblerRobert & Jane Toll FoundationStephen J. TormaDorothy M. & Edward TostiWalter TsouCarole A. TuckerRalph C. UlisseSteven WallMichael WarnerJoanne WatermanLorie & William WatkinsSusan & Scott E. WechslerRaymond WeickerEllen R. WeissAnna M. WendrychowiczRobert Werkman

Jason WildmanStephen J. WilliamsJan WilliamsonJane K. WindleMarlene & Michael T. WislerMeghan WisnieskiMaurice M. WitkinAnthony J. WongDiane Dalto & Richard E. WoosnamDebra WuerschMargaret M. YaussiLeslie YoungCollette L. ZimmerAndrea & Mark ZukorRenee M. & Joseph S. ZuritskyAnthony J. Zysk

Corporations, Foundations, and Other OrganizationsAcme Markets, Inc.Aetna FoundationAHEPA Cancer Research Foundation,

Fifth District American Cancer Research Center &

FoundationARC Roofing CorporationAsbestos Workers Local 14

Mesothelioma FundAstraZeneca PharmaceuticalsAuxilium Board of DirectorsBF Molz, Inc.The Barra FoundationBeckman Coulter FoundationBiogen IdecBoard of Associates of Fox Chase

Cancer CenterBucks County ChapterCoastal FriendsDevlin Fund for Cancer ResearchMarlyn R. Fein ChapterFox Chase ChapterFriends of the Hospital The Trading Post

Breast Cancer Relief FoundationBristol-Myers Squibb FoundationBuckl & Jankowski ArchitectsC.H. Robinson Worldwide, Inc.Caley-Groves TrustCelgeneCephalon, Inc.Chain Reaction for a CureColligas Family Markets, LPCovidienCrown Holdings, Inc.Desouza Brown, Inc.Dia-NielsenThe Ellison Medical FoundationEnterprise Rent-A-Car

FoundationErnest Bock & Sons, Inc.EwingColeExxonMobil FoundationRocheFalcon Foundation First National ServicesFox & Roach Charities

Faculty & Staff of Fox Chase Cancer Center

H.B. Frazier CompanyGE FoundationGem Land CompanyGenentech, Inc.Genomic Health, Inc.Genuardi’s MarketsGlaxoSmithKlineGoldsteins’ Rosenberg’s

Raphael-SacksHerman Goldner Co., Inc.Thornton D. & Elizabeth S. Hooper

FoundationHoyle, Fickler Herschel & Mathes LLPI-Flow CorporationING FoundationITW FoundationEileen Stein Jacoby FundJewish Community FoundationJewish Federation of Southern

New JerseyJohnson & JohnsonJuriStaff, Inc.Kay Construction Management Corp.F. M. Kirby FoundationSusan G. Komen for the CureL.E.K. Consulting, LLCLamar Advertising CompanyLiberty Mutual FoundationEli Lilly and CompanyMacy’s FoundationThe McGrorty Foundation, Inc.McNeil Consumer HealthcareMennonite FoundationMerck & Co., Inc.Merrill Lynch FoundationMillennium Pharmaceuticals, Inc.National Ovarian Cancer CoalitionOld Mutual Investment Partners, Inc.Olympus America Inc.OSI PharmaceuticalsP. Agnes, Inc.The Philadelphia FoundationPrevent Cancer FoundationThe Prudential FoundationThe Quaker Chemical Foundationsanofi-aventis, U.S. INCThe Scholler FoundationThe W. W. Smith Charitable TrustSunoco FoundationTeal Ribbon Ovarian Cancer Research

Foundation, Inc.Team Tommy Z “A Day In The Park”Tuberous Sclerosis AllianceUnited States Roofing CorporationUnited Way AgenciesVerizon FoundationVon Morris CorporationWawaWest Pharmaceutical Services, Inc.Wright-Cook FoundationZach Attacks Cancer


2807W2:2807W2 3/10/10 3:46 PM Page 46

Annual Fund

Unrestricted annual gifts support the over-all Fox Chase mission and can be used tomeet the Center’s most pressing needs. Annual support of $1,000 or more qualifiesdonors as members of the Laurel Society.

Major Gifts

Those interested in providing leadershipphilanthropic support to a particular program may wish to do so through themajor gifts program. The major gifts teamcan help to match individual interests with key initiatives and provide informationon establishing endowments, naming opportunities, and priority program areasthat need support.

Gifts of Securities

The donation of appreciated securities canresult in significant tax benefits. Appreci-ated securities owned for more than a yeargenerate a charitable income tax deductionfor the securities’ current market value. Inaddition, donors avoid capital gains tax onthe appreciation in value.

Workplace Giving and Matching Gifts

Donors may elect to support Fox Chasethrough participation in the United Way orCombined Federal campaigns. They alsocan make the most of their donations byparticipating in a matching gift program.Ask your human resources department ifFox Chase is a designated charity in yourworkplace and whether your employermatches charitable gifts, or visitwww.fccc.edu/helpingfoxchase/makeAGift.

Planned Giving

Supporters can contribute throughout alifetime or through an estate with a plannedgift such as a bequest, life insurance policy,annuity, real estate, or retirement plan. The Center’s planned giving staff can helpdesign a giving strategy that integrates intoan individual’s overall estate plans and provides a meaningful contribution to Fox Chase.

• • •

For more information or to make a tax-deductible gift, visit www.fccc.edu/helpingFoxChase or call the Office of InstitutionalAdvancement at 215-728-2745.

For patients and families who wish to support Fox Chase, an array of givingoptions are available to meet a variety of interests and financial situations.Fox Chase is grateful for gifts of all sizes; each one makes a difference.

WAYS TO GIVE SUPPORTING FOX CHASE

“I put myself in the shoes of my mom’s [health-care] team. They spend their lives helping other people who are struggling, and I wanted to do something to help them.”

Zach Herr, 14, donor and son of a patient

THE ELIZABETH ANDERSON SOCIETYHonoring a Vision

In 2009, Fox Chase established the Elizabeth Anderson Society tohonor the thoughtful patients andfriends who have made gifts to the Center as part of their financialplanning. The gifts have taken multiple forms, including bequests, gift annuities, charitable trusts, life insurance policies, retirement accounts, and real estate.

The society is named for a generousearly benefactor. In 1906, the fledg-ling cancer hospital that would become Fox Chase was only twoyears old, but patient ElizabethAnderson, a friend of a trustee, hadsuch confidence in the people therethat she bequeathed $40,000—theequivalent of $900,000 today—to support the facility. She gave tosupport a vision of progress, hope,and discovery against a dreadedand poorly understood disease.

The Elizabeth Anderson Societypays tribute to Fox Chase friendswho make a commitment toprogress in cancer science andmedicine by making planned giftsto Fox Chase. For more informationon the society or on making FoxChase part of your estate plans,contact the Office of InstitutionalAdvancement at 215-728-2745.


2807W2:2807W2 3/10/10 3:46 PM Page 47

2807W2:2807W2 3/10/10 3:47 PM Page 48

FACULTY &LEADERSHIP

“Technology doesn’t revolutionize medicine; people do. And places like Fox Chase are where the revolution is happening.”

Robert G. Uzzo, Chairman, Department of Surgery

2807W2:2807W2 3/10/10 3:47 PM Page 49

CLINICALDEPARTMENT OF CLINICAL GENETICS

Mary B. Daly, M.D., Ph.D., Chairwoman

Angela R. Bradbury, M.D.Veda N. Giri, M.D.Michael J. Hall, M.D.

DEPARTMENT OF DIAGNOSTICIMAGINGRosaleen B. Parsons, M.D., Chairwoman

David S. Ball, D.O.Richard J. Daniels, M.D.Kristin Wolcott Edwards, M.D.Kathryn A. Evers, M.D.Marlane C. Guttmann, M.D.Stephen A. Leschak, M.D.Barton N. Milestone, M.D.Samuel G. Putnam III, M.D.Jian Q. Yu, M.D.

DEPARTMENT OF MEDICAL ONCOLOGY

Massimo Cristofanilli, M.D., Chairman

Igor Astsaturov, M.D., Ph.D.Hossein Borghaei, D.O.Barbara Ann Burtness, M.D.Jonathan D. Cheng, M.D.Marcin Chwistek, M.D.Adam D. Cohen, M.D.Roger B. Cohen, M.D.Steven J. Cohen, M.D.Crystal S. Denlinger, M.D.Holly Dushkin, M.D. Scot W. Ebbinghaus, M.D.Robert V. Emmons, M.D.1

Paul F. Engstrom, M.D. Lori J. Goldstein, M.D.Gary R. Hudes, M.D.Patricia Kropf, M.D.1

Michael H. Levy, M.D., Ph.D.Gregory Michael Lubiniecki, M.D. Kenneth F. Mangan, M.D.1

Lainie P. Martin, M.D.Mary Ellen Martin, M.D.1

Ranee Mehra, M.D.Michael M. Millenson, M.D.Tara Morrison, M.D.Anthony J. Olszanski, M.D.Elizabeth R. Plimack, M.D. Russell Schilder, M.D.Michael V. Seiden, M.D., Ph.D.George R. Simon, M.D. Mitchell R. Smith, M.D., Ph.D.Neeta Somaiah, M.D.Ramona F. Swaby, M.D.Joseph Treat, M.D.Margaret von Mehren, M.D.Yu-Ning Wong, M.D.

DEPARTMENT OF MEDICINE

David S. Weinberg, M.D., Chairman

DermatologyStuart R. Lessin, M.D.Clifford S. Perlis, M.D.Matthew B. Zook, M.D., Ph.D.

GastroenterologyDavid S. Weinberg, M.D.Gregory H. Enders, M.D., Ph.D.Oleh Haluszka, M.D.Stephen J. Heller, M.D.Minhhuyen T. Nguyen, M.D.Jeffrey L. Tokar, M.D.

Hospitalist ServiceRichard F. Dietrick, M.D.Mala T. Kailasam, M.D.Amy R. MacKenzie, M.D.

PsychiatryKaren Y. Mechanic, M.D.Emmie I. Chen, M.D.Michelle Rodoletz, Ph.D.

Pulmonary ServiceAlan David Haber, M.D. Earl D. King, M.D.Michael Unger, M.D.

DEPARTMENT OF PATHOLOGY

Arthur S. Patchefsky, M.D., Chairman

Harry S. Cooper, M.D.Tahseen I. Al-Saleem, M.D.Hormoz Ehya, M.D.Douglas B. Flieder, M.D.Karen S. Gustafson, M.D., Ph.D.Min Huang, M.D., Ph.D.Valentin G. Robu, M.D., Ph.D.Hong Wu, M.D., Ph.D.

DEPARTMENT OF RADIATION ONCOLOGY

Eric M. Horwitz, M.D., Chairman

Penny R. Anderson, M.D.Mark K. Buyyounouski, M.D. Gary M. Freedman, M.D.Shelly Bowers Hayes, M.D.Nicolas K. Kuritzky, M.D.C-M Charlie Ma, Ph.D.Nicos Nicolaou, M.D.1

Mark L. Sobczak, M.D.Brij M. Sood, M.D.3

Aruna Turaka, M.D.

DEPARTMENT OF SURGICAL ONCOLOGY

Robert G. Uzzo, M.D., Chairman

Cynthia A. Bergman, M.D. Richard J. Bleicher, M.D.Stephen A. Boorjian, M.D.Robert Allen Burger, M.D. David Y. T. Chen, M.D. Yun Shin Chun, M.D.Jeffrey M. Farma, M.D. Richard E. Greenberg, M.D. Andrew A. Gumbs, M.D.John P. Hoffman, M.D. Sarah H. Kim, M.D.Miriam N. Lango, M.D.Douglas W. Laske, M.D.2

Chris Loftus, M.D.2

Avi Lebenthal, M.D.Mark A. Morgan, M.D. Sameer A. Patel, M.D.John A. Ridge, M.D., Ph.D. Walter J. Scott, M.D. Neal S. Topham, M.D.Richard G. Schmidt, M.D. Elin R. Sigurdson, M.D., Ph.D. Rosalia Viterbo, M.D.James C. Watson, M.D. Michael Weaver, M.D.2

Anesthesiology David J. Fish, M.D.James L. Helstrom, M.D.Kristin K.G. Krauss, M.D.Lynn E. Morgenlander, M.D.Mark-Alan D. Pizzini, M.D.Murray Suskin, M.D.

1 Member of Fox Chase-Temple Bone MarrowTransplant Program

2 Member of Fox Chase-Temple Neuro-Oncology Program

3 Director, PinnacleHealth-Fox Chase Regional Cancer Center


FACULTY MEMBERS

2807W2:2807W2 3/10/10 3:47 PM Page 50

RESEARCHCANCER BIOLOGY

Program LeadersJonathan Chernoff, M.D., Ph.D.Joseph R. Testa, Ph.D.

Primary MembersAlfonso Bellacosa, M.D., Ph.D.Stephen A. Boorjian, M.D.* Paul Cairns, Ph.D.Edna Cukierman, Ph.D.Gregory H. Enders, M.D., Ph.D.* Hua-Ying Fan, Ph.D.Gary R. Hudes, M.D.* Richard Katz, Ph.D.Andres J.P. Klein-Szanto, M.D., Ph.D.Alfred G. Knudson Jr., M.D., Ph.D.Vladimir M. Kolenko, M.D., Ph.D.Warren D. Kruger, Ph.D.Biao Luo, Ph.D.Beatrice Mintz, Ph.D.Alana O’Reilly, Ph.D.Jeffrey R. Peterson, Ph.D.Fabrice Roegiers, Ph.D.Alexei Tulin, Ph.D.Robert G. Uzzo, M.D.* Hong Yan, Ph.D.Tim J. Yen, Ph.D.

CANCER PREVENTION AND CONTROL

Program LeadersCarolyn Y. Fang, Ph.D.Margie L. Clapper, Ph.D.

Primary Members Andrea M. Barsevick, Ph.D.Angela R. Bradbury, M.D.* Mary B. Daly, M.D., Ph.D.* Paul F. Engstrom, M.D.* Linda Fleisher, Ph.D.(c)Veda N. Giri, M.D.* Michael J. Hall, M.D.* Carolyn J. Heckman, Ph.D.Amy B. Lazev, Ph.D.Sharon L. Manne, Ph.D.Suzanne M. Miller, Ph.D.Pamela Shapiro, Ph.D.David S. Weinberg, M.D.* Yu-Ning Wong, M.D.*

IMMUNE CELL DEVELOPMENT AND HOST DEFENSE

Program LeadersGlenn F. Rall, Ph.D.David L. Wiest, Ph.D.

Primary MembersTahseen I. Al-Saleem, M.D.* Siddharth Balachandran, Ph.D.Kerry S. Campbell, Ph.D.Adam D. Cohen, M.D.* Richard R. Hardy, Ph.D.Kyoko Hayakawa, M.D., Ph.D.Dietmar J. Kappes, Ph.D.William S. Mason, Ph.D.

Jennifer Rhodes, Ph.D.Valentin G. Robu, M.D., Ph.D.*Christoph Seeger, Ph.D.Luis J. Sigal, D.V.M., Ph.D.Anna M. Skalka, Ph.D.Mitchell R. Smith, M.D., Ph.D.* John M. Taylor, Ph.D.

DEVELOPMENTAL THERAPEUTICS

Program LeadersGregory P. Adams, Ph.D.Erica A. Golemis, Ph.D.Roger B. Cohen, M.D.*

Primary MembersIgor Astsaturov, M.D., Ph.D.* Zimei Bu, Ph.D.Hossein Borghaei, D.O.* Barbara Burtness, M.D.* Mark K. Buyyounouski, M.D.* Lili Chen, M.D., Ph.D.Steven J. Cohen, M.D.* Mohan Doss, Ph.D.Roland L. Dunbrack Jr., Ph.D.Elizabeth Hopper-Borge, Ph.D.Eileen K. Jaffe, Ph.D.Stuart R. Lessin, M.D.* Ranee Mehra, M.D.* Maureen E. Murphy, Ph.D.Anthony J. Olszanski, M.D.* John A. Ridge, M.D., Ph.D.* Matthew K. Robinson, Ph.D.Heinrich Roder, Ph.D.George R. Simon, M.D.* Margaret von Mehren, M.D.* Anthony T. Yeung, Ph.D.Jian Q. Yu, M.D., Ph.D.*

WOMEN’S CANCER

Program LeadersAndrew K. Godwin, Ph.D.Massimo Cristofanilli, M.D.*

Primary MembersJeff Boyd, Ph.D.Robert A. Burger, M.D.* Xiaowei Chen, Ph.D.Denise C. Connolly, Ph.D.Joanne F. Dorgan, Ph.D.Lori J. Goldstein, M.D.* Thomas C. Hamilton, Ph.D.Lainie P. Martin, M.D.* Mark A. Morgan, M.D.* Irma H. Russo, M.D.Jose Russo, M.D.Russell J. Schilder, M.D.* Michael V. Seiden, M.D., Ph.D.* Elin R. Sigurdson, M.D., Ph.D.* Ramona F. Swaby, M.D.* Joan Lewis-Wambi, Ph.D.Rugang Zhang, Ph.D.

* Member of clinical faculty

ChairmanDavid G. Marshall

Vice ChairmenW. Thacher Brown Louis E. Della Penna Sr. Thomas W. Hofmann Margot W. Keith Peter McCausland

Members William J. AveryG. Morris Dorrance Jr.The Hon. Dwight EvansEdward A. GlickmanThomas W. HofmannLawrence T. Hoyle Jr., Esq.Philip E. Lippincott William G. LittleDonald E. Morel Jr., Ph.D.Jane G. PepperEdward J. RoachThomas Shenk, Ph.D.Pamela StrisofskyThomas R. Tritton, Ph.D.Kenneth E. WegJerry Wind, Ph.D.

Members EmeretiFrank G. Binswanger Jr.Ira R. Dolich A.J. Gabriele Nancy E. Goldy William S. Woods Jr.

Sustaining MembersCarolyn Aldigé Jenne K. Britell, Ph.D. Robert E. Brown Jr. Valerie C. FergusonArgeris N. Karabelas, Ph.D.Malcolmn D. Pryor

Ex Officio MembersDebra Sniger Michael V. Seiden, M.D., Ph.D.

Current as of March 20, 2010

BOARD OF DIRECTORS


2807W2:2807W2 3/10/10 3:47 PM Page 51


SENIORADMINISTRATORS

BOARDOF ASSOCIATES

OFFICERS

PresidentDebra Sniger

TreasurerCorinne R. Roxby

Executive Member-at-largeBarbara Klimowicz

Vice Presidents

INTERNAL AFFAIRS, BYLAWS AND PUBLICITY

Elizabeth Rizor

OUTREACH AND EDUCATION

Jeanne Nace

AFFILIATES AND NEW CHAPTERS

Linda and Bob Devlin

Honorary OfficersIra and Arline DolichJudith GoldbergJean A. Isaacs Donald & Martha LeedyMargaret Merjanian Robert C. Young, M.D.

CHAPTER OFFICERS

Bucks County Chapter

PresidentLillian M. O’Connor

First Vice PresidentDaniel S. Levin

Second Vice PresidentWilliam W. Langan

Recording SecretaryElizabeth Rizor

Corresponding SecretaryPatricia Bachtle

TreasurerRhea M. Brown

Fox Chase Chapter

PresidentJanet F. Engstrom

First Vice PresidentElaine R. Reimet

Second Vice PresidentMarsha Eisenberg

Corresponding SecretaryGina Kremp

TreasurerCorinne R. Roxby

Friends of the Hospital of Fox Chase Cancer Center

PresidentMaryann Gauntt

Executive Vice PresidentTammie Hutt

First Vice President, MembershipDawn Hatch

Second Vice President, Ways and Means

Jeanne Nace

Recording SecretarySuzanne Alven

TreasurerKellie Clark

Marlyn R. Fein Chapter

PresidentPenny Fisher

Vice PresidentsSelma Bell Harriet Kauffman

Recording SecretaryDebbie Holman

Financial SecretaryCorinne Greenberg

TreasurerTrudy Smugar

Trading Post Chapter

PresidentElizabeth Anthony

First Vice President Sharon Pici

Second Vice President Lisa Leff

SecretaryBill Jones

TreasurerLinda Epps

AFFILIATES

Jimbo’s Squad Jaclyn and Brian McShane

South Jersey Affiliate May M. Brill

The Devlin Fund for Cancer Researchat Fox Chase Cancer Center

Linda and Bob Devlin

EDITORAbbey J. Porter

CONTRIBUTING WRITERSGeorge BeschenJennifer Baldino BonettThomas W. DursoJill M. ErcolinoAlison FritzMartha LedgerSandra Salmans

DESIGNGHI Design

PHOTOGRAPHYKarl Seifert: faculty, patient, anddonor portraits

Supporting photography:Jessica HuiJoe HurleyTommy LeonardiJim Roese

PRINTINGInnovation Printing

The annual report is produced by the communications department ofFox Chase Cancer Center. Inquiries: E-mail [email protected] or call 215-728-3699.

Fox Chase Cancer Center333 Cottman AvenuePhiladelphia, PA 19111-24971-888-FOX CHASE (1-888-369-2427)www.FoxChase.org

Fox Chase Cancer Center is one of theleading cancer research and treatmentcenters in the United States. Foundedin 1904 as one of the nation’s first cancer hospitals, it was also amongthe first institutions to earn the prestigious comprehensive cancercenter designation from the NationalCancer Institute.

Michael V. Seiden, M.D., Ph.D.President and Chief Executive Officer

J. Robert Beck, M.D.Senior Vice President; Chief Academic Officer;Chief Medical Officer

Jeff Boyd, Ph.D.Senior Vice President; Chief Scientific Officer

Paul F. Engstrom, M.D.Senior Vice President, Extramural Research Program;Chief Network Officer

Joseph F. Hediger Jr.Senior Vice President; Chief Financial Officer

Susan H. TofaniSenior Vice President, Clinical Services and Business Development

Robert G. Wilkens Jr.Senior Vice President, Institutional Advancement; Chief Development Officer

Gary J. WeyhmullerSenior Vice President; Chief Operating Officer

National Comprehensive Cancer Network®

www.LoveVersusCancer.org

Join us in recognizingthe power of love.

2807W2:2807W2 3/10/10 3:47 PM Page 52

against cancer

Documents